Search

Your search keyword '"Cui J"' showing total 13,992 results
Start Over Author "Cui J"
13,992 results on '"Cui J"'

1. Heterologous Prime-Boost Immunization Strategies Using Varicella-Zoster Virus gE mRNA Vaccine and Adjuvanted Protein Subunit Vaccine Triggered Superior Cell Immune Response in Middle-Aged Mice

Author

Li D, Bian L, Cui L, Zhou J, Li G, Zhao X, Xing L, Cui J, Sun B, Jiang C, Kong W, Zhang Y, and Chen Y

Subjects
varicella-zoster virus, mrna vaccine, glycoprotein e, lipid nanoparticles, heterologous prime-boost, cell-mediated immunity, Medicine (General), R5-920
Abstract

Dongdong Li,1 Lijun Bian,1 Lili Cui,2 Jingying Zhou,1 Gaotian Li,1 Xiaoyan Zhao,1 Liao Xing,1 Jiaxing Cui,1 Bo Sun,1 Chunlai Jiang,1,3,4 Wei Kong,1,3,4 Yong Zhang,1,3,4 Yan Chen1,3,4 1National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, People’s Republic of China; 2Beijing Institute of Drug Metabolism, Beijing, People’s Republic of China; 3Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Sciences, Jilin University, Changchun, People’s Republic of China; 4NMPA Key Laboratory of Humanized Animal Models for Evaluation of Vaccines and Cell Therapy Products, Jilin University, Changchun, People’s Republic of ChinaCorrespondence: Yan Chen; Yong Zhang, National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, 130012, People’s Republic of China, Tel +86-431-85167751, Fax +86-431-85167674, Email chen_yan0417@126.com; zhypharm@jlu.edu.cnPurpose: Heterologous immunization using different vaccine platforms has been demonstrated as an efficient strategy to enhance antigen-specific immune responses. In this study, we performed a head-to-head comparison of both humoral and cellular immune response induced by different prime-boost immunization regimens of mRNA vaccine and adjuvanted protein subunit vaccine against varicella-zoster virus (VZV) in middle-aged mice, aiming to get a better understanding of the influence of vaccination schedule on immune response.Methods: VZV glycoprotein (gE) mRNA was synthesized and encapsulated into SM-102-based lipid nanoparticles (LNPs). VZV-primed middle-aged C57BL/6 mice were then subjected to homologous and heterologous prime-boost immunization strategies using VZV gE mRNA vaccine (RNA-gE) and protein subunit vaccine (PS-gE). The antigen-specific antibodies were evaluated using enzyme-linked immunosorbent assay (ELISA) analysis. Additionally, cell-mediated immunity (CMI) was detected using ELISPOT assay and flow cytometry. Besides, in vivo safety profiles were also evaluated and compared.Results: The mRNA-loaded lipid nanoparticles had a hydrodynamic diameter of approximately 130 nm and a polydispersity index of 0.156. Total IgG antibody levels exhibited no significant differences among different immunization strategies. However, mice received 2×RNA-gE or RNA-gE>PS-gE showed a lower IgG1/IgG2c ratio than those received 2×PS-gE and PS-gE> RNA-gE. The CMI response induced by 2×RNA-gE or RNA-gE>PS-gE was significantly stronger than that induced by 2×PS-gE and PS-gE> RNA-gE. The safety evaluation indicated that both mRNA vaccine and protein vaccine induced a transient body weight loss in mice. Furthermore, the protein vaccine produced a notable inflammatory response at the injection sites, while the mRNA vaccine showed no observable inflammation.Conclusion: The heterologous prime-boost strategy has demonstrated that an mRNA-primed immunization regimen can induce a better cell-mediated immune response than a protein subunit-primed regimen in middle-aged mice. These findings provide valuable insights into the design and optimization of VZV vaccines with the potentials to broaden varicella vaccination strategies in the future.Keywords: varicella-zoster Virus, mRNA vaccine, glycoprotein E, lipid nanoparticles, heterologous prime-boost, cell-mediated immunity

Published
2024

2. Inflammation Can Be a High-Risk Factor for Mucosal Nonunion of MRONJ by Regulating SIRT1 Signaling When Treated with an Oncologic Dose of Zoledronate

Author

Zhu S, Cui Y, Zhang W, Ji Y, Li L, Luo S, Cui J, and Li M

Subjects
mronj, mucosal healing, inflammation, oxidative stress, mitochondrial dysfunction, sirt1, Therapeutics. Pharmacology, RM1-950
Abstract

Siqi Zhu,1– 3,* Yajun Cui,2,3,* Weidong Zhang,2,3 Yu Ji,2,3 Lingshuang Li,2,3 Shenglei Luo,4 Jing Cui,5,6 Minqi Li2,3 1School of Stomatology, Jinzhou Medical University, Jinzhou, People’s Republic of China; 2Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, Jinan, People’s Republic of China; 3Center of Osteoporosis and Bone Mineral Research, Shandong University, Jinan, People’s Republic of China; 4Department of Oral and Maxillofacial Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, People’s Republic of China; 5Department of Oral and Maxillofacial Surgery, Jinan Stomatological Hospital, Jinan, People’s Republic of China; 6Central Laboratory, Jinan Key Laboratory of oral tissue regeneration, Shandong Provincial Health Commission Key Laboratory of Oral Diseases and Tissue Regeneration, Jinan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jing Cui, Department of Oral and Maxillofacial Surgery, Jinan Stomatological Hospital, Jinglv Road 101, Jinan, 250001, People’s Republic of China, Tel +86-0531-86261960, Email 2005cuijing@163.com Minqi Li, Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, Wenhua West Road 44-1, Jinan, 250012, People’s Republic of China, Tel +86-0531-88382095, Email liminqi@sdu.edu.cnPurpose: Zoledronate (ZA) stands as a highly effective antiresorptive agent known to trigger medication-related osteonecrosis of the jaw (MRONJ). Its clinical dosages primarily encompass those used for oncologic and osteoporosis treatments. While inflammation is recognized as a potential disruptor of mucosal healing processes associated with ZA, prior research has overlooked the influence of varying ZA dosages on tissue adaptability. Therefore, a deeper understanding of the specific mechanisms by which inflammation exacerbates ZA-induced MRONJ, particularly when inflammation acts as a risk factor, remains crucial.Methods: Cell proliferation and migration of human oral keratinocytes (HOK) was analyzed after treatment with different doses of ZA and/or lipopolysaccharide (LPS) to assess their possible effect on mucosal healing of extraction wounds. Mouse periodontitis models were established using LPS, and histological changes in extraction wounds were observed after the administration of oncologic dose ZA. Hematoxylin and eosin (HE) staining and immunofluorescence were used to evaluate mucosal healing.Results: In vitro, LPS did not exacerbate the effects of osteoporosis therapeutic dose of ZA on the proliferation and migration of HOK cells, while aggravated these with the oncologic dose of ZA treatment by inducing mitochondrial dysfunction and oxidative stress via regulating SIRT1 expression. Furthermore, SIRT1 overexpression can alleviate this process. In vivo, local injection of LPS increased the nonunion of mucous membranes in MRONJ and decreased the expression of SIRT1, PGC-1α, and MnSOD.Conclusion: Inflammation aggravates oncologic dose of ZA-induced mitochondrial dysfunction and oxidative stress via a SIRT1-dependent pathway, enhancing the risk of impaired mucosal healing in MRONJ. Our study implies that inflammation becomes a critical risk factor for MRONJ development at higher ZA concentrations. Elucidating the mechanisms of inflammation as a risk factor for mucosal non-healing in MRONJ could inform the development of SIRT1-targeted therapies.Keywords: MRONJ, mucosal healing, inflammation, oxidative stress, mitochondrial dysfunction, SIRT1

Published
2024

3. Novel L-(CaP-ZnP)/SA Nanocomposite Hydrogel with Dual Anti-Inflammatory and Mineralization Effects for Efficient Vital Pulp Therapy

Author

Zhang X, Zhou X, Zhai W, Cui J, Pan Z, Du L, Wen L, Ye R, Zhang B, Huang L, Li D, Wang C, and Sun H

Subjects
nanocomposite hydrogel, vital pulp therapy, pulpitis, p38 signaling pathway, Medicine (General), R5-920
Abstract

Xu Zhang,1,* Xue Zhou,2,* Wenhao Zhai,1,* Jing Cui,1 Ziyi Pan,1 Liuyi Du,1 Linlin Wen,1 Rongrong Ye,1 Boya Zhang,1 Lei Huang,1 Daowei Li,1 Chungang Wang,2 Hongchen Sun1 1Jilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, Hospital of Stomatology, Jilin University, Changchun, 130021, People’s Republic of China; 2Department of Chemistry, Northeast Normal University, Changchun, 130024, People’s Republic of China*These authors contributed equally to this workCorrespondence: Daowei Li; Lei Huang, Email jluldw@jlu.edu.cn; huanglei17@mails.jlu.edu.cnBackground: Vital pulp therapy (VPT) is considered a conservative treatment for preserving pulp viability in caries and trauma-induced pulpitis. However, Mineral trioxide aggregate (MTA) as the most frequently used repair material, exhibits limited efficacy under inflammatory conditions. This study introduces an innovative nanocomposite hydrogel, tailored to simultaneously target anti-inflammation and dentin mineralization, aiming to efficiently preserve vital pulp tissue.Methods: The L-(CaP-ZnP)/SA nanocomposite hydrogel was designed by combining L-Arginine modified calcium phosphate/zinc phosphate nanoparticles (L-(CaP-ZnP) NPs) with sodium alginate (SA), and was characterized with TEM, SEM, FTIR, EDX, ICP–AES, and Zeta potential. In vitro, we evaluated the cytotoxicity and anti-inflammatory properties. Human dental pulp stem cells (hDPSCs) were cultured with lipopolysaccharide (LPS) to induce an inflammatory response, and the cell odontogenic differentiation was measured and possible signaling pathways were explored by alkaline phosphatase (ALP)/alizarin red S (ARS) staining, qRT-PCR, immunofluorescence staining, and Western blotting, respectively. In vivo, a pulpitis model was utilized to explore the potential of the L-(CaP-ZnP)/SA nanocomposite hydrogel in controlling pulp inflammation and enhancing dentin mineralization by Hematoxylin and eosin (HE) staining and immunohistochemistry staining.Results: In vitro experiments revealed that the nanocomposite hydrogel was synthesized successfully and presented desirable biocompatibility. Under inflammatory conditions, compared to MTA, the L-(CaP-ZnP)/SA nanocomposite hydrogel demonstrated superior anti-inflammatory and pro-odontogenesis effects. Furthermore, the nanocomposite hydrogel significantly augmented p38 phosphorylation, implicating the involvement of the p38 signaling pathway in pulp repair. Significantly, in a rat pulpitis model, the L-(CaP-ZnP)/SA nanocomposite hydrogel downregulated inflammatory markers while upregulating mineralization-related markers, thereby stimulating the formation of robust reparative dentin.Conclusion: The L-(CaP-ZnP)/SA nanocomposite hydrogel with good biocompatibility efficiently promoted inflammation resolution and enhanced dentin mineralization by activating p38 signal pathway, as a pulp-capping material, offering a promising and advanced solution for treatment of pulpitis. Keywords: nanocomposite hydrogel, vital pulp therapy, pulpitis, p38 signaling pathway

Published
2024

4. A Novel Continuous Sleep State Artificial Neural Network Model Based on Multi-Feature Fusion of Polysomnographic Data

Author

Cui J, Sun Y, Jing H, Chen Q, Huang Z, Qi X, and Cui H

Subjects
sleep depth value, sleep continuity, eeg features, timing fitness, ann model, Psychiatry, RC435-571, Neurophysiology and neuropsychology, QP351-495
Abstract

Jian Cui,1 Yunliang Sun,2 Haifeng Jing,3 Qiang Chen,1 Zhihao Huang,1 Xin Qi,1 Hao Cui1 1Department of Big Data and Fundamental Sciences, Shandong Institute of Petroleum and Chemical Technology, Dongying, Shandong, 257061, People’s Republic of China; 2Department of Respiratory and Sleep Medicine, Bin Zhou Medical University Hospital, Binzhou, Shandong, 256600, People’s Republic of China; 3College of Software and Microelectronics, Peking University, Beijing, 100000, People’s Republic of ChinaCorrespondence: Jian Cui, Department of Big Data and Fundamental Sciences, Shandong Institute of Petroleum and Chemical Technology, 271 Bei Er Lu, Dongying City, Shandong Province, 257061, People’s Republic of China, Tel +86-15066073763, Email jian.cui@sdipct.edu.cnPurpose: Sleep structure is crucial in sleep research, characterized by its dynamic nature and temporal progression. Traditional 30-second epochs falter in capturing the intricate subtleties of various micro-sleep states. This paper introduces an innovative artificial neural network model to generate continuous sleep depth value (SDV), utilizing a novel multi-feature fusion approach with EEG data, seamlessly integrating temporal consistency.Methods: The study involved 50 normal and 100 obstructive sleep apnea–hypopnea syndrome (OSAHS) participants. After segmenting the sleep data into 3-second intervals, a diverse array of 38 feature values were meticulously extracted, including power, spectrum entropy, frequency band duration and so on. The ensemble random forest model calculated the timing fitness value for all the features, from which the top 7 time-correlated features were selected to create detailed sleep sample values ranging from 0 to 1. Subsequently, an artificial neural network (ANN) model was trained to delineate sleep continuity details, unravel concealed patterns, and far surpassed the traditional 5-stage categorization (W, N1, N2, N3, and REM).Results: The SDV changes from wakeful stage (mean 0.7021, standard deviation 0.2702) to stage N3 (mean 0.0396, standard deviation 0.0969). During the arousal epochs, the SDV increases from the range (0.1 to 0.3) to the range around 0.7, and decreases below 0.3. When in the deep sleep (≤ 0.1), the probability of arousal of normal individuals is less than 10%, while the average arousal probability of OSA patients is close to 30%.Conclusion: A sleep continuity model is proposed based on multi-feature fusion, which generates SDV ranging from 0 to 1 (representing deep sleep to wakefulness). It can capture the nuances of the traditional five stages and subtle differences in microstates of sleep, considered as a complement or even an alternative to traditional sleep analysis.Keywords: sleep depth value, sleep continuity, EEG features, timing fitness, ANN model

Published
2024

5. Clinical Efficacy and Safety of a Modified Moxibustion Therapy for Low Back Pain in Lumbar Disc Herniation: A Two-Center, Randomized, Controlled, Non-Inferiority Trial

Author

Xue K, Wang X, Xiao C, Zhang N, Liu M, Fu J, and Cui J

Subjects
ldh, low back pain, ma's bamboo-based medicinal moxibustion, acupuncture, randomized controlled trial, Medicine (General), R5-920
Abstract

Kaiyang Xue,1 Xianzhu Wang,1 Caihong Xiao,2 Ning Zhang,1 Minghui Liu,3 Jing Fu,1 Jin Cui1 1College of Acupuncture and Massage, Guizhou University of Traditional Chinese Medicine, Guiyang, 550002, People’s Republic of China; 2Department of Acupuncture and Moxibustion, No.1 Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, 550001, People’s Republic of China; 3Department of Acupuncture and Moxibustion, No.2 Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, 550001, People’s Republic of ChinaCorrespondence: Jin Cui, College of Acupuncture and Massage, Guizhou University of Traditional Chinese Medicine, No. 50 Shidong Road, Nanming District, Guiyang, 550002, People’s Republic of China, Email 516260179@qq.comObjective: Our pilot study shows that a modified moxibustion therapy called Ma’s bamboo-based medicinal moxibustion can alleviate the symptoms of low back pain in lumbar disc herniation (LDH), and has the potential to treat LDH. The aim of this study is to evaluate the efficacy and safety of Ma’s bamboo-based medicinal moxibustion for low back pain in LDH.Methods: A total of 312 LDH patients with low back pain were randomized to receive Ma’s bamboo-based medicinal moxibustion (MBMM) or acupuncture (AT). The primary efficacy measure was the change of Visual Analogue Scale (VAS) on the 14th day compared with that at baseline. The secondary efficacy measures included VAS score, Oswestry disability index (ODI), modified Japanese Orthopaedic Association (M-JOA) score, and the content of β-endorphin (β-EP) and substance-P (SP). The safety measures included the occurrence of adverse events and the changes in laboratory indicators.Results: In total, 304 patients were incorporated for the analysis of efficacy, including 96 males and 208 females, aged 21– 65 years. There was no statistically significant difference in the change of VAS score between the two groups on the 14th day [mean difference (95% CI) = − 2.31 (− 2.48, − 2.13) and − 2.28 (− 2.45, − 2.11), respectively; p = 0.819]. The VAS, ODI, and M-JOA scores changed after the intervention in both groups (p < 0.001), with increased β-EP content (p = 0.014, p = 0.032) and decreased SP content (p < 0.001, p = 0.048). The ODI score (p = 0.039) and M-JOA score (p = 0.032) of the MBMM group on the 28th day were lower than those of the AT group.Conclusion: The efficacy of Ma’s bamboo-based medicinal moxibustion therapy in relieving low back pain of LDH patients is comparable to that of acupuncture, and it has post-effect advantages in improving lumbar dysfunction and daily living ability, which can be used as a safe and effective alternative method for LDH treatment.Keywords: LDH, low back pain, Ma’s bamboo-based medicinal moxibustion, acupuncture, randomized controlled trial

Published
2024

6. The Effectiveness and Safety of Acupuncture for Mammary Hyperplasia: A Systematic Review and Meta-Analysis

Author

Li J, Zhang D, Hu J, Cui J, and Mansoor KM

Subjects
acupuncture, mammary hyperplasia, efficacy, meta-analysis, review, safety, Medicine (General), R5-920
Abstract

Jifeng Li,1 Dongxiao Zhang,1 Jing Hu,1 Jianchun Cui,2 Khattak Mazher Mansoor2 1Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, People’s Republic of China; 2Liaoning Provincial People’s Hospital (Department of Thyroid and Breast Surgery, People’s Hospital of China Medical University), Shenyang, People’s Republic of ChinaCorrespondence: Dongxiao Zhang, Department of Galactophore, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23, Art Museum Back Street, Dongcheng District, Beijing, 100010, People’s Republic of China, Tel +8617864190977, Email morningdong@163.comObjective: This study aims to systematically evaluate the effectiveness and safety of acupuncture in treating mammary hyperplasia.Methods: A comprehensive search was conducted in various databases, including PubMed, Web of Science, Cochrane Library, Embase, SinoMed, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP Database, from their inception until July 2023. Only randomized controlled trials (RCTs) researching the use of acupuncture for mammary hyperplasia were included. Quality assessment and data analysis were performed using RevMan 5.3 software.Results: Eight RCTs, comprising 573 patients, were included in this analysis. The meta-analysis revealed that in the acupuncture group, the experimental group was better than the control group in improving breast pain, breast lump extent, and the texture of breast lump (P=0.0007, I2=61%; P=0.02, I2=0%; P=0.0002, I2=0%). We found that both could be improved, but after statistical analysis, there was no significant advantage in the acupuncture group compared with the patent Chinese medicine group (p> 0.05).Conclusion: Acupuncture appears to be an effective and safe treatment for mammary hyperplasia, providing pain relief and reducing mass volume, texture, and extent. However, the insufficient quality of the available evidence indicates the need for further methodologically rigorous and convincingly designed studies to determine the efficacy and safety of acupuncture in the treatment of breast hyperplasia.Keywords: acupuncture, mammary hyperplasia, efficacy, meta-analysis, review, safety

Published
2024

7. Emotional Exhaustion and Emotional Contagion: Navigating Turnover Intention of Healthcare Personnel

Author

Feng Y and Cui J

Subjects
emotional contagion, emotional exhaustion, role overload, turnover intention, job demands-resources model, Medicine (General), R5-920
Abstract

Yisong Feng,1 Jing Cui2 1College of Public Health, Chongqing Medical University, Chongqing, People’s Republic of China; 2Human Resources Office, Chongqing Medical University, Chongqing, People’s Republic of ChinaCorrespondence: Jing Cui, Human Resources Office, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, People’s Republic of China, Tel +86-13708360542, Fax +862368480072, Email cuijing@cqmu.edu.cnPurpose: This study aimed to examine the role of personal emotions and emotional contagion within organizations on the behavior and attitudes of healthcare personnel. This study is expected to provide a theoretical foundation for reducing resignation behaviors and improving healthcare quality.Materials and Methods: This study adopted a quantitative research method with a cross-sectional survey through an online questionnaire. The bootstrap method with 5000 iterations was used to validate the role of variables within a 95% confidence interval. SPSS 26.0 and Model 5 in Process 3.4 for SPSS were used for the data analysis.Results: This research involved 459 healthcare personnel, whose levels of role overload (3.821± 0.925), emotional exhaustion (3.436± 1.189), and turnover emotional contagion (3.110± 1.099) were notably high. Role overload was positively related to turnover intention, with emotional exhaustion as a mediator. Notably, turnover emotional contagion exerted a positive moderating effect.Conclusion: This study emphasizes the adverse effects of emotional exhaustion and turnover emotional contagion in the Chinese context, offering practical recommendations for medical organizational managers to navigate turnover intention among healthcare personnel. This study suggests paying attention to the emotional state of healthcare personnel and providing adequate support resources. Managers should routinely assess and track turnover emotional contagion within the organization, fostering a positive emotional atmosphere.Keywords: emotional contagion, emotional exhaustion, role overload, turnover intention, job demands-resources model

Published
2024

8. Fractional Excretion of Urate is Positively Associated with Type 2 Diabetes in HUA Patients: A Cross-Sectional Study

Author

Huang B, Li X, Zhang X, Li S, Liu Y, Zhang M, and Cui J

Subjects
urine uric acid excretion (uuae), hyperuricemia, obesity, type 2 diabetes, fractional excretion of urate (feua)., Specialties of internal medicine, RC581-951
Abstract

Bo Huang,&ast; Xin Li,&ast; Xinxin Zhang, Shiwei Li, Yue Liu, Mengjuan Zhang, Jingqiu Cui Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jingqiu Cui, Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, 300052, People’s Republic of China, Tel +86 13920765604, Email cuijingqiu@tmu.edu.cnPurpose: People with hyperuricemia (HUA) are often related to metabolic disorders such as diabetes, metabolic syndrome (MetS), and obesity. However, the correlation between excretion of uric acid and these diseases is unclear. Our study aimed to explore the relationship between uric acid excretion and type 2 diabetes (T2D).Methods: A total of 228 HUA patients from Tianjin Medical University General Hospital from 2022 to 2023 were included in this study. We collected demographic, biochemical, and anthropometric data on each subject. Urine uric acid excretion (UUAE) was calculated enzymatically from a single urine collection that lasted 24 hours. And fractional excretion of uric acid (FEUA) was calculated from serum uric acid and creatinine and uric acid and creatinine. Binary logistic regression modeling assessed the association between uric acid excretion and T2D.Results: Of the 228 subjects, 13.4% had T2D and 48.7% had obesity. The obesity group had a lower FEUA (p< 0.05) and a higher UUAE compared to the control group (p< 0.05). And FEUA had a stronger correlation with the risk of T2D (p< 0.001). Also, there was a negative association between BMI and FEUA and a positive link between BMI and UUAE in the outpatients.Conclusion: Increased FEUA levels were significantly associated with T2D in HUA patients. Therefore, routine calculating of FEUA is essential for proper diagnosis and appropriate treatment T2D of in HUA patients. Keywords: urine uric acid excretion, hyperuricemia, obesity, Type 2 diabetes, fractional excretion of urate

Published
2024

9. Silencing KLF6 Alleviates Cigarette Smoke Extract-Induced Mitochondrial Dysfunction in Bronchial Epithelial Cells by SIRT4 Upregulation

Author

Wan M, Wang C, Cui J, Xia Q, and Zhang L

Subjects
klf6, sirt4, copd, cse, mitochondrial dysfunction, Diseases of the respiratory system, RC705-779
Abstract

Menghong Wan, Chen Wang, Jiamin Cui, Qing Xia, Lei Zhang Caoyang Community Health Service Center, Shanghai, 200063, People’s Republic of ChinaCorrespondence: Lei Zhang, Caoyang Community Health Service Center, No. 121 Lanxi Street, Putuo District, Shanghai, 200063, People’s Republic of China, Email Zhanglei_871007@163.comBackground: The incidence of chronic obstructive pulmonary disease (COPD) is increasing year by year. Kruppel-like factor 6 (KLF6) plays an important role in inflammatory diseases. However, the regulatory role of KLF6 in COPD has not been reported so far.Methods: The viability of human bronchial epithelial cells BEAS-2B induced by cigarette smoke extract (CSE) was detected by CCK-8 assay. The protein expression of KLF6 and sirtuin 4 (SIRT4) was appraised with Western blot. RT-qPCR and Western blot were applied to examine the transfection efficacy of sh-KLF6 and Oe-KLF6. Cell apoptosis was detected using flow cytometry. The levels of inflammatory factors IL-6, TNF-α and IL-1β were assessed with ELISA assay. DCFH-DA staining was employed for the detection of ROS activity and the levels of oxidative stress markers SOD, CAT and MDA were estimated with corresponding assay kits. The mitochondrial membrane potential (MMP), adenosine triphosphate (ATP) content and Complex I activity were evaluated with JC-1 staining, ATP colorimetric/fluorometric assay kit and Complex I enzyme activity microplate assay kit. With the application of mitochondrial permeability transition pore detection kit, mPTP opening was measured. Luciferase report assay was employed to evaluate the activity of SIRT4 promoter and chromatin immunoprecipitation (ChIP) to verify the binding ability of KLF6 and SIRT4 promoter.Results: KLF6 expression was significantly elevated in CSE-induced cells. KLF6 was confirmed to suppress SIRT4 transcription. Interference with KLF6 expression significantly inhibited cell viability damage, cell apoptosis, inflammatory response, oxidative stress and mitochondrial dysfunction in CSE-induced BEAS-2B cells, which were all reversed by SIRT4 overexpression.Conclusion: Silencing KLF6 alleviated CSE-induced mitochondrial dysfunction in bronchial epithelial cells by SIRT4 upregulation.Keywords: KLF6, SIRT4, COPD, CSE, mitochondrial dysfunction

Published
2024

10. Species Distribution, Typical Clinical Features and Risk Factors for Poor Prognosis of Super-Elderly Patients with Bloodstream Infection in China

Author

Cui J, Li Y, Du Q, Wei Y, Liu J, and Liang Z

Subjects
bloodstream infection, elderly, species, risk factor, mortality, aging, central venous catheter, clinical feature, Infectious and parasitic diseases, RC109-216
Abstract

Jiewei Cui,1,&ast; Yang Li,2,&ast; Qingyan Du,3,&ast; Yuanhui Wei,1 Jinxia Liu,1 Zhixin Liang1 1College of Pulmonary & Critical Care Medicine, 8th Medical Center of Chinese PLA General Hospital, Beijing, 100091, People’s Republic of China; 2Department of Pulmonary and Critical Care Medicine, The First Hospital of Shanxi Medical University, Taiyuan, 030001, People’s Republic of China; 3Jiamei Dental Hospital, Beijing, 100143, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Zhixin Liang, Email liangzhixin301@163.comObjective: Bloodstream infection (BSI) is characterized by high mortality, especially among these increasing super-elderly patients (≥ 85 years), and this study was conducted to understand the species distribution, typical clinical features and risk factors for poor prognosis of super-elderly patients with BSI.Methods: Based on previous work, this retrospective study was performed by reviewing an ongoing prospective medical database in a comprehensive tertiary center in China, and all super-elderly patients with BSI in the past 6 years were enrolled in this study.Results: Out of 5944 adult-patients with BSI, there were totally 431 super-elderly patients (≥ 85 years old) enrolled in this study and age ≥ 90 years accounted for 31.1% (134/431). Among these 431 super-elderly patients with BSI, 40 patients (9.3%) were diagnosed with BSI and the remained 401 super-elderly patients (90.7%) were defined as hospital-acquired BSI. The typical feature of these super-elderly patients with BSI was the high proportion of patients with various comorbidities, such as cardiovascular disease (83.8%), ischemic cerebrovascular disease (63.3%) and pulmonary infection (61.0%). The other typical feature was that most (60.1%) of these patients had been hospitalized for long time (≥ 28 days) prior to the onset of BSI, and most patients had received various invasive treatments, such as indwelling central venous catheter (53.1%) and indwelling urinary catheter (47.1%). Unfortunately, due to these adverse features above, both the 7-day short-term mortality (13.2%, 57/431) and the 30-day long-term mortality (24.8%, 107/431) were high. The multivariate analysis showed that both chronic liver failure (OR 7.9, 95% CI 2.3– 27.8, P=0.001) and indwelling urinary catheter (OR 2.3, 95% CI 1.1– 4.7, P=0.023) were independent risk factors for 7-day short-term mortality, but not for 30-day long-term mortality. In addition, the microbiology results showed that the most common species were associated with nosocomial infection or self-opportunistic infection, such as Staphylococcus hominis (18.3%), Staphylococcus epidermidis (11.8%), Escherichia coli (9.7%), Klebsiella pneumoniae (9.3%) and Candida albicans (8.6%, fungi).Conclusion: Super-elderly patients with BSI had typical features, regardless of the pathogenic species distribution and their drug resistance, or clinical features and their risk factors for poor prognosis. These typical features deserved attention and could be used for the prevention and treatment of BSI among super-elderly patients.Keywords: bloodstream infection, elderly, species, risk factor, mortality, aging, central venous catheter, clinical feature

Published
2024

11. Prognostic Factors and Construction of Nomogram Prediction Model of Lung Cancer Patients Using Clinical and Blood Laboratory Parameters

Author

Zhang Y, Wan W, Shen R, Zhang B, Wang L, Zhang H, Ren X, Cui J, and Liu J

Subjects
laboratory parameters, lc, nomogram prediction model, km analysis, cox multivariate analysis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Yamin Zhang,1 Wei Wan,1 Rui Shen,1 Bohao Zhang,1 Li Wang,1 Hongyi Zhang,2 Xiaoyue Ren,3 Jie Cui,4,&ast; Jinpeng Liu1,&ast; 1Department of Oncology, Xi’an International Medical Center Hospital, Xi’an, Shaanxi, 710100, People’s Republic of China; 2Department of Urology, The First Affiliated Hospital of Xi’an Medical University, Xi’an, Shaanxi, 710077, People’s Republic of China; 3College of Life Sciences, Northwest University, Xi’an, Shaanxi, 710069, People’s Republic of China; 4Department of Oncology, The First Affiliated Hospital of Xi’an Medical University, Xi’an, Shaanxi, 710077, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jie Cui, Department of Oncology, The First Affiliated Hospital of Xi’an Medical University, No. 48 Fenghao West Road, Lianhu District, Xi’an, Shaanxi, 710077, People’s Republic of China, Tel/Fax +86-15209277121, Email cuicui780204@163.com Jinpeng Liu, Department of Oncology, Xi’an International Medical Center Hospital, No. 777, Xitai Road, Chang’an District, Xi’an, Shaanxi, 710100, People’s Republic of China, Tel/Fax +86-13772079179, Email lekai0822@163.comObjective: This work aimed to explore the prognostic risk factors of lung cancer (LC) patients and establish a line chart prediction model.Methods: A total of 322 LC patients were taken as the study subjects. They were randomly divided into a training set (n = 202) and a validation set (n = 120). Basic information and laboratory indicators were collected, and the progression-free survival (PFS) and overall survival (OS) were followed up. Single-factor and cyclooxygenase (COX) multivariate analyses were performed on the training set to construct a Nomogram prediction model, which was validated with 120 patients in the validation set, and Harrell’s consistency was analyzed.Results: Single-factor analysis revealed significant differences in PFS (P< 0.05) between genders, body mass index (BMI), carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), squamous cell carcinoma antigen (SCCA), treatment methods, treatment response evaluation, smoking status, presence of pericardial effusion, and programmed death ligand 1 (PD-L1) at 0 and 1– 50%. Significant differences in OS (P< 0.05) were observed for age, tumor location, treatment methods, White blood cells (WBC), uric acid (UA), CA125, pro-gastrin-releasing peptide (ProGRP), SCCA, cytokeratin fragment 21 (CYFRA21), and smoking status. COX analysis identified male gender, progressive disease (PD) as treatment response, and SCCA > 1.6 as risk factors for LC PFS. The consistency indices of the line chart models for predicting PFS and OS were 0.782 and 0.772, respectively.Conclusion: Male gender, treatment response of PD, and SCCA > 1.6 are independent risk factors affecting the survival of LC patients. The PFS line chart model demonstrates good concordance.Keywords: laboratory parameters, LC, nomogram prediction model, KM analysis, cox multivariate analysis

Published
2024

12. Identification and Analysis of ZIC-Related Genes in Cerebellum of Autism Spectrum Disorders

Author

Li H, Cui J, Hu C, Luo X, and Hao Y

Subjects
autism, zic1, zic2, zic3, cerebellum, biomarkers., Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Heli Li,1,&ast; Jinru Cui,1,&ast; Cong Hu,1 Hao Li,2 Xiaoping Luo,3 Yan Hao1 1Division of Child Healthcare, Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 2Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 3Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Yan Hao, Email haoyaner@163.comObjective: Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with significant genetic heterogeneity. The ZIC gene family can regulate neurodevelopment, especially in the cerebellum, and has been implicated in ASD-like behaviors in mice. We performed bioinformatic analysis to identify the ZIC gene family in the ASD cerebellum.Methods: We explored the roles of ZIC family genes in ASD by investigating (i) the association of ZIC genes with ASD risk genes from the Simons Foundation Autism Research Initiative (SFARI) database and ZIC genes in the brain regions of the Human Protein Atlas (HPA) database; (ii) co-expressed gene networks of genes positively and negatively correlated with ZIC1, ZIC2, and ZIC3, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, and receiver operating characteristic (ROC) curve analysis of genes in these networks; and (iii) the relationship between ZIC1, ZIC2, ZIC3, and their related genes with cerebellar immune cells and stromal cells in ASD patients.Results: (i) ZIC1, ZIC2, and ZIC3 were associated with neurodevelopmental disorders and risk genes related to ASD in the human cerebellum and (ii) ZIC1, ZIC2, and ZIC3 were highly expressed in the cerebellum, which may play a pathogenic role by affecting neuronal development and the cerebellar internal environment in patients with ASD, including immune cells, astrocytes, and endothelial cells. (iii) OLFM3, SLC27A4, GRB2, TMED1, NR2F1, and STRBP are closely related to ZIC1, ZIC2, and ZIC3 in ASD cerebellum and have good diagnostic accuracy. (iv) ASD mice in the maternal immune activation model demonstrated that Zic3 and Nr2f1 levels were decreased in the immune-activated cerebellum.Conclusion: Our study supports the role of ZIC1, ZIC2, and ZIC3 in ASD pathogenesis and provides potential targets for early and accurate prediction of ASD.Keywords: autism, ZIC1, ZIC2, ZIC3, cerebellum, biomarkers

Published
2024

13. New Insights into Roles of IL-7R Gene as a Therapeutic Target Following Intracerebral Hemorrhage

Author

Cui J, Wang H, Liu S, and Zhao Y

Subjects
immune infiltration, intracerebral hemorrhage, cibersort algorithm, il-7 receptor, Pathology, RB1-214, Therapeutics. Pharmacology, RM1-950
Abstract

Jie Cui,1– 4,&ast; Hongbin Wang,5,6,&ast; Shiyao Liu,1– 4 Yiming Zhao1– 4 1Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People’s Republic of China; 2National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People’s Republic of China; 3NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People’s Republic of China; 4Collaborative Innovation Center of Hematology, Soochow University, Suzhou, 215006, People’s Republic of China; 5Department of Emergency, Jiangyin Hospital of Traditional Chinese Medicine, Wuxi, 214400, People’s Republic of China; 6Department of Intensive Care Unit, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Yiming Zhao, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People’s Republic of China, Tel +86-512-67781379, Fax +86-512-65113556, Email zhaoyimingbox@163.comBackground: Spontaneous intracerebral hemorrhage (ICH) is a subtype of stroke leading to high rates of morbidity and mortality in adults. Recent studies showed that immune and inflammatory responses might play essential roles in secondary brain injury. The purpose of this article was to provide a reference for further therapeutic strategies for ICH patients.Methods: GSE206971 and GSE216607 datasets from the gene expression omnibus (GEO) database were used to screen the highly immune-related differentally expressed genes (IRDEGs). We used the CIBERSORT algorithm to assess the level of immune signatures infiltration and got the possible function of IRDEGs which was analyzed through Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Protein-protein interaction (PPI) networks and six hub genes were identified in the Cytoscape plug-in. GSVA algorithm was performed to evaluate the potential pathways of six hub genes in ICH samples. The expression level of IL-7R chosen from six hub genes was further validated by Western blotting. The cell models of ICH were established for the research of IL-7/IL-7R signaling way.Results: A total of six hub genes (ITGAX, ITGAM, CCR2, CD28, SELL, and IL-7R) were identified. IL-7R was highly expressed in the mice ICH group, as shown by immunoblotting. Next, we constructed ICH cell models in RAW264.7 cells and BV2 cells. After treatment with IL-7, iNOS expression (M1 marker) was greatly inhibited while Arg-1(M2 marker) was enhanced, and it might function via the JAK3/STAT5 signaling pathway.Conclusion: The hypothesis is proposed that the IL-7/IL-7R signaling pathway might regulate the inflammatory process following ICH by regulating microglia polarization. Our study is limited and requires more in-depth experimental confirmation.Keywords: immune infiltration, intracerebral hemorrhage, CIBERSORT algorithm, IL-7 receptor

Published
2024

14. Panax quinquefolium L. and Salvia miltiorrhiza Bunge. Enhances Angiogenesis by Regulating the miR-155-5p/HIF-1α/VEGF Axis in Acute Myocardial Infarction

Author

Li X, Liu R, Liu W, Liu X, Fan Z, Cui J, Wu Y, Yin H, and Lin Q

Subjects
panax quinquefolium l, salvia miltiorrhiza bunge, angiogenesis, acute myocardial infarction, mir-155-5p/hif-1α/vegf, Therapeutics. Pharmacology, RM1-950
Abstract

Xingxing Li,1 Rongpeng Liu,1 Wei Liu,1 Xin Liu,2 Zongjing Fan,1 Jie Cui,1 Yang Wu,1 Huijun Yin,3 Quan Lin1 1Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, People’s Republic of China; 2The Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, 100029, People’s Republic of China; 3Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, People’s Republic of ChinaCorrespondence: Quan Lin, Dongfang Hospital, Beijing University of Chinese Medicine, No. 6, Fangxingyuan District 1, Fengtai District, Beijing, 100078, People’s Republic of China, Tel +86-10-67689757, Email linquanys@163.comBackground: Combination of Panax quinquefolium L and Salvia miltiorrhiza Bunge. (PS) has been widely used in the clinical treatment of ischemic heart disease. The purpose of this study was to explore the therapeutic effect and mechanism of PS on angiogenesis in rats after acute myocardial infarction (AMI).Methods: A rat model of AMI was established by ligating the left anterior descending (LAD) artery. The grouping and administration scheme were as follows: sham group, model group, PS low-dose (PS-L) group, PS high-dose (PS-H) group, PX-478 group and angiotensin converting enzyme inhibitor (ACEI) group. After 28 days of treatment, echocardiography, myocardial infarct size, some angiogenesis markers and the miR-155-5p/HIF-1α/VEGF axis were measured.Results: PS improved cardiac structure and function, reduced infarct size, and alleviated myocardial fibrosis and inflammatory cell infiltration in AMI rats. Mechanistically, PS enhanced the expression of HGF and bFGF in serum, increased the levels of MVD and CD31 in myocardial tissues, and inhibited the activation of the miR-155-5p/HIF-1α/VEGF pathway, which ultimately promoted angiogenesis. In addition, the regulatory effect of PS on angiogenesis was partly abolished by PX-478.Conclusion: PS increased the expression of MVD and CD31 in the myocardium and stimulated angiogenesis. The above effects of PS may be associated with the inhibition of the miR-155-5p/HIF-1α/VEGF axis. Keywords: Panax quinquefolium L, Salvia miltiorrhiza Bunge, angiogenesis, acute myocardial infarction, miR-155-5p/HIF-1α/VEGF

Published
2023

15. Manganese-Based Nanotheranostics for Magnetic Resonance Imaging-Mediated Precise Cancer Management

Author

Du R, Zhao Z, Cui J, and Li Y

Subjects
manganese, magnetic resonance imaging, precise diagnosis, targeted therapy, malignant tumor, Medicine (General), R5-920
Abstract

Ruochen Du,1 Ziwei Zhao,2,&ast; Jing Cui,3,&ast; Yanan Li2 1Department of Laboratory Animal Center, Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China; 2College of Medical Imaging, Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China; 3College of Public Health, Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Yanan Li, College of Medical Imaging, Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China, Email liyanan0213@sxmu.edu.cnAbstract: Manganese (Mn)-based magnetic resonance imaging (MRI) has become a competitive imaging modality for cancer diagnosis due to its advantages of non-invasiveness, high resolution and excellent biocompatibility. In recent years, a variety of Mn contrast agents based on different material systems have been synthesized, and a series of multi-purpose Mn nanocomposites have also emerged, showing satisfactory relaxation efficiency and MRI performance thus possess the transformation and application value in MRI-synergized cancer diagnosis and treatment. This tutorial review starts from the classification and properties of Mn-based nanomaterials, and then summarizes various preparation and functionalization strategies of nanosized Mn contrast agents, especially focuses on the latest progress of Mn contrast agents in MRI-synergized precise cancer theranostics. In addition, present review also discusses the current clinical transformation obstacles such as unclear molecular mechanisms, potential nanotoxicity, and scale production constraints. This paper provides evidence-based recommendations about the future prospects of multifunctional nanoplatforms, as well as technical guidance and panoramic expectations for the design of clinically meaningful cancer management programs.Keywords: manganese, magnetic resonance imaging, precise diagnosis, targeted therapy, malignant tumor

Published
2023

16. Risk Factors for Granulomatous Mastitis and Establishment and Validation of a Clinical Prediction Model (Nomogram)

Author

Zeng Y, Zhang D, Fu N, Zhao W, Huang Q, Cui J, Chen Y, Liu Z, Zhang X, Zhang S, and Mansoor KM

Subjects
granulomatous mastitis, risk factors, case-control study, nomogram, prediction model, Public aspects of medicine, RA1-1270
Abstract

Yifei Zeng,1,2 Dongxiao Zhang,1 Na Fu,1 Wenjie Zhao,1 Qiao Huang,1 Jianchun Cui,3 Yunru Chen,4 Zhaolan Liu,4 Xiaojun Zhang,5 Shiyun Zhang,6 Khattak Mazher Mansoor3 1Department of Galactophore, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, People’s Republic of China; 2Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 3Liaoning Provincial People’s Hospital (Department of Thyroid and Breast Surgery, People’s Hospital of China Medical University), Shenyang, People’s Republic of China; 4Centre for Evidence-Based Chinese Medicine, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 5Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, People’s Republic of China; 6Guang’ Anmen Hospital, China Academy of Chinese Medical Science, Beijing, People’s Republic of ChinaCorrespondence: Dongxiao Zhang, Department of Galactophore, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23, Art Museum Back Street, Dongcheng District, Beijing, 100010, People’s Republic of China, Tel +86 17862968916, Email morningdong@163.comBackground: This study aimed to explore the risk factors and clinical characteristics of granulomatous mastitis (GM) using a case-control study and establish and validate a clinical prediction model (nomogram).Methods: This retrospective case-control study was conducted in three hospitals in China from June 2017 to December 2021. A total of 1634 GM patients and 186 healthy women during the same period were included and randomly divided into the modeling and validation groups in a 7:3 ratio. To identify the independent risk factors of GM, univariate and multivariate logistic analyses were conducted and used to develop a nomogram. The prediction model was internally and externally validated using the Bootstrap technique and validation cohort. The receiver operating characteristic (ROC) curve and calibration curve were used to evaluate the discrimination and calibration of the prediction model. Decision curve analysis (DCA) and clinical impact curve (CIC) were used to evaluate the clinical significance of the model.Results: The average age of GM patients was 33.14 years (mainly 20– 40). The incidence was high within five years from delivery and mainly occurred in the unilateral breast. The majority of the patients exhibited local skin alterations, while some also presented with systemic symptoms. On multivariate logistic analysis, age, high prolactin level, sex hormone intake, breast trauma, nipple discharge or invagination, and depression were independent risk factors for GM. The mean area under the curve (AUC) in the modeling and validation groups were 0.899 and 0.889. The internal and external validation demonstrated the model’s predictive ability and clinical value.Conclusion: Lactation-related factors are the main risk factors of GM, leading to milk stasis or increased ductal secretion. Meanwhile, hormone disorders could affect the secretion and expansion of mammary ducts. All these factors can obstruct or injure the duct, inducing inflammatory reactions and immune responses. Additionally, blunt trauma, depressed mood, and diet preference can accelerate the process. The nomogram can effectively predict the risk of GM.Keywords: granulomatous mastitis, risk factors, case-control study, nomogram, prediction model

Published
2023

17. Hsa_circ_0007823 Overexpression Suppresses the Progression of Triple-Negative Breast Cancer via Regulating miR-182-5p-FOXO1 Axis

Author

Yu J, Wang H, Shen W, Zhou Y, Cui J, Li H, and Gao B

Subjects
triple-negative breast cancer, hsa_circ_0007823, mir-182, foxo1, biological functional analysis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Jinling Yu,1 Haofeng Wang,1 Weida Shen,1 Yingzi Zhou,2 Jing Cui,1 Haichuan Li,3 Beimin Gao1 1Department of Breast Surgery, Shanghai Changning Maternity and Infant Health Hospital, East China Normal University, Shanghai, 200050, People’s Republic of China; 2Department of Pathology, Shanghai Changning Maternity and Infant Health Hospital, East China Normal University, Shanghai, 200050, People’s Republic of China; 3Department of Laboratory, Shanghai Changning Maternity and Infant Health Hospital, East China Normal University, Shanghai, 200050, People’s Republic of ChinaCorrespondence: Beimin Gao; Haichuan Li, Shanghai Changning Maternity and Infant Health Hospital, East China Normal University, No. 786, Yuyuan Road, Changning District, Shanghai, 200050, People’s Republic of China, Tel +86-21-62288686-2401, Email gbgaobeimin@163.com; lihaichuancfy@163.comBackground: This study aimed to analyze the specific expression of hsa_circ_0007823 in triple-negative breast cancer (TNBC) and explore the roles and related molecular mechanisms of hsa_circ_0007823 in TNBC.Materials and Methods: Relative hsa_circ_0007823 levels in TNBC tissues and cell lines were examined by reverse transcription-quantitative polymerase chain reaction. The value of hsa_circ_0007823 levels was evaluated in patients’ clinicopathological characteristics and prognostic prediction. A dual-luciferase reporter assay was used to determine the relationship between hsa_circ_0007823, miR-182-5p, and FOXO1. The effect of circ_0007823 overexpression on the growth of TNBC cells was investigated in vitro and in vivo.Results: Lower levels of hsa_circ_0007823 were found in TNBC tissues and cell lines and were closely associated with lymph node metastasis, poorer overall and disease-free survival rates. MiR-182-5p was significantly up-regulated, whereas FOXO1 was down-regulated in TNBC cell lines. The miR-182-5p inhibition up-regulated FOXO1 in TNBC cells. Dual-luciferase reporter assays showed that hsa_circ_0007823, miR-182-5p, and FOXO1 interacted with each other. Overexpression of circ_0007823 significantly inhibited the viability, migration, and invasion of TNBC cell lines, but promoted apoptosis. In vivo experiments showed that circ_0007823 overexpression inhibited tumor growth and down-regulated miR-182-5p and up-regulated FOXO1.Conclusion: Hsa_circ_0007823 overexpression could suppress the growth, invasion, and migration of TNBC cells, and inhibit tumor growth by regulating miR-182-5p/FOXO1.Keywords: triple-negative breast cancer, hsa_circ_0007823, miR-182, FOXO1, biological functional analysis

Published
2023

18. In vitro Antimicrobial Activity and Dose Optimization of Eravacycline and Other Tetracycline Derivatives Against Levofloxacin-Non-Susceptible and/or Trimethoprim-Sulfamethoxazole-Resistant Stenotrophomonas maltophilia

Author

Wu J, Zhang G, Zhao Q, Wang L, Yang J, and Cui J

Subjects
eravacycline tetracyclines levofloxacin trimethoprim, sulfamethoxazole drug combination stenotrophomonas maltophilia monte carlo method, Infectious and parasitic diseases, RC109-216
Abstract

Jie Wu,1,2 Guangcun Zhang,3 Qiang Zhao,3 Lifeng Wang,3 Jiyong Yang,3 Junchang Cui1 1Department of Respiratory Diseases, The Eighth Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, People’s Republic of China; 2Medical School of Chinese People’s Liberation Army, Beijing, People’s Republic of China; 3Laboratory Medicine Department, The First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, People’s Republic of ChinaCorrespondence: Junchang Cui, The Eighth Medical Center, Department of Respiratory Diseases, Chinese People’s Liberation Army General Hospital, No. 17 Heishanhu Road, Haidian District, Beijing, 100091, People’s Republic of China, Tel +86 010 6677 5010, Email guoguoyoumeng@163.comPurpose: To better guide clinical use, we determined the in vitro antimicrobial activity of the new drug eravacycline and other tetracycline derivatives against levofloxacin (LVFX)-non-susceptible and/or trimethoprim-sulfamethoxazole (TMP-SMZ)-resistant Stenotrophomonas maltophilia and evaluated their dosing regimens.Methods: Seventy-seven unique strains of S. maltophilia were isolated from sputa samples and airway aspirate samples that were either LVFX-non-susceptible and/or TMP-SMZ-resistant. Monte Carlo simulations were performed for different dosing regimens according to the population pharmacokinetic parameters of antibiotics in patients with respiratory tract infections at the minimum inhibitory concentration (MIC).Results: Eravacycline had excellent in vitro antibacterial activity against LVFX-non-susceptible and/or TMP-SMZ-resistant S. maltophilia. Monte Carlo simulations showed that for LVFX-non-susceptible strains, the cumulative fraction of response (CFR) of minocycline at the conventional recommended dose of 100 mg q12 h was 90.90%; for TMP-SMZ-resistant strains, the CFR of minocycline at a high dose of 200 mg q12 h was only 91.64%. For strains resistant to both LVFX and TMP-SMZ, the CFR of minocycline at a high dose of 200 mg q12 h was 89.81%. In contrast, the CFR of tigecycline was less than 40%, even at a dose of 100 mg q12 h.Conclusion: For pneumonia, minocycline is better for S. maltophilia that is non-susceptible to LVFX; for TMP-SMZ-resistant strains and strains that are not susceptible to either LVFX or TMP-SMZ, the efficiency of eravacycline requires further evaluation. Eravacycline may be a better choice for extremely resistant S. maltophilia strains that are non-susceptible to LVFX, TMP-SMZ, and minocycline.Keywords: eravacycline, tetracyclines, levofloxacin, trimethoprim, sulfamethoxazole drug combination, Stenotrophomonas maltophilia, Monte Carlo method

Published
2023

19. AI-Assisted Ultrasound for the Early Diagnosis of Antibody-Negative Autoimmune Thyroiditis

Author

Yao S, Zhang B, Fei X, Xiao M, Lu L, Liu D, Zhang S, and Cui J

Subjects
antibody negative, autoimmune thyroiditis, hypothyroidism, hypoechoic thyroid, artificial intelligence, hashimoto's disease, Medicine (General), R5-920
Abstract

Shengsheng Yao,1,&ast; Bo Zhang,2,&ast; Xiang Fei,3 Mingming Xiao,4 Li Lu,5 Daming Liu,6 Siyuan Zhang,7 Jianchun Cui3 1China Medical University - Department of Thyroid and Breast Surgery, Liaoning Provincial People’s Hospital, Shenyang, Liaoning Province, 110015, People’s Republic of China; 2Department of Science and Education, The 10th Division of Xinjiang Production and Construction Corps, Beitun General Hospital, Beitun City, Xinjiang Province, 831300, People’s Republic of China; 3Department of Thyroid and Breast Surgery, People’s Hospital of China Medical University (Liaoning Provincial People’s Hospital), Shenyang, Liaoning Province, 110015, People’s Republic of China; 4Department of Pathology, People’s Hospital of China Medical University (Liaoning Provincial People’s Hospital), Shenyang, Liaoning Province, 110015, People’s Republic of China; 5Department of Endocrinology, People’s Hospital of China Medical University (Liaoning Provincial People’s Hospital), Shenyang, Liaoning Province, 110015, People’s Republic of China; 6Department of Ultrasound, People’s Hospital of China Medical University (Liaoning Provincial People’s Hospital), Shenyang, Liaoning Province, 110015, People’s Republic of China; 7Department of Thyroid and Breast Surgery, The 10th Division of Xinjiang Production and Construction Corps, Beitun General Hospital, Beitun City, Xinjiang Province, 831300, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jianchun Cui, Department of Thyroid and Breast Surgery, People’s Hospital of China Medical University (Liaoning Provincial People’s Hospital), No. 33 of Wenyi Road, Shenhe District, Shenyang, Liaoning Province, 110015, People’s Republic of China, Tel +86 24 24016014, Fax +86 24 24016014, Email cjc7162003@aliyun.comAbstract: The prevalence of antibody-negative chronic autoimmune thyroiditis (SN-CAT) is increasing. The early diagnosis of SN-CAT can effectively prevent its further development. Thyroid ultrasound can diagnose autoimmune thyroiditis and predict hypothyroidism. Primary hypothyroidism with a hypoechoic pattern suggested by thyroid ultrasound and negative thyroid serum antibodies is the main basis for the diagnosis of SN-CAT. However, for early SN-CAT, only hypoechoic thyroid changes and serological antibodies are currently available. This study explored how to achieve an accurate and early diagnosis of SN-CAT and prevent the development of SN-CAT combined with hypothyroidism. The diagnosis of a hypoechoic thyroid by artificial intelligence is expected to be a breakthrough in the accurate diagnosis of SN-CAT.Keywords: antibody negative, autoimmune thyroiditis, hypothyroidism, hypoechoic thyroid, artificial intelligence, Hashimoto’s disease

Published
2023

20. The New Changes of Epidemiology, Etiology, and Clinical Characteristics of Pyogenic Liver Abscesses: A Retrospective Study in a Hospital in Northern China

Author

Cui J, Liu Y, and Li J

Subjects
pyogenic liver abscess, morbidity, pathogen, diabetes, klebsiella pneumoniae, Infectious and parasitic diseases, RC109-216
Abstract

JinHua Cui,1 YaMan Liu,2 Jian Li1 1Department of Hepatobiliary Surgery, Affiliated Hospital of Chengde Medical College, Chengde City, Hebei Province, People’s Republic of China; 2Department of Gynaecology, Affiliated Hospital of Chengde Medical College, Chengde City, Hebei Province, People’s Republic of ChinaCorrespondence: Jian Li, Department of Hepatobiliary Surgery, Affiliated Hospital of Chengde Medical College, Chengde City, Hebei Province, People’s Republic of China, Tel +8615127811018, Email lijian1008@126.comPurpose: To investigate the epidemiology, etiology, and clinical characteristics of patients with pyogenic liver abscesses (PLA) and provide guidance for clinical treatments.Patients and Methods: A retrospective study was performed on a cohort of 402 hospitalized patients diagnosed with PLAs at the Affiliated Hospital of Chengde Medical College between January 2016 and December 2021. Patient demographics, drug sensitivity profiles, and microbiological culture results of drainage and blood samples were thoroughly analyzed to identify significant patterns or trends. Furthermore, clinical characteristics and treatments for patients with PLA were comprehensively assessed.Results: Patients aged 50– 69 years had the highest incidence of PLA, accounting for 59.9% of all cases, and 91.5% of them had a fever. Bacterial culture analysis of the 200 patients revealed that Klebsiella pneumoniae (K. pneumoniae) was the most predominant pathogen, detected in 70.5% of cases, exhibiting an upward trend. Escherichia coli (E. coli) was the second most frequently detected pathogen, identified in 14.5% of cases, showing a downward trend. Coexisting diabetes mellitus (DM) was found to be the most common comorbidity for PLA, occurring in most patients with the condition. Patients with a history of abdominal surgery and malignancy had an increased risk for PLA, while those with gallstones had a decreased risk. Drainage combined with antibiotic therapy was identified as the primary treatment of PLA. In addition, multivariate analysis demonstrated that coexisting DM and the presence of gas in the abscess cavity were independent risk factors for septic shock in patients with PLA.Conclusion: This study reveals a shift in the proportions of pathogens and risk factors in patients with PLA, underscoring the necessity for improved diagnostic and therapeutic strategies.Keywords: pyogenic liver abscess, morbidity, pathogen, diabetes, Klebsiella pneumoniae

Published
2023

21. Myopenic Obesity Determined by Fat Mass Percentage Predicts Risk of Aspirin-Induced Bleeding in Chinese Older Adults

Author

Wang X, Li L, Cui J, Cheng M, and Liu M

Subjects
myopenic obesity, aspirin-induced bleeding, body composition, percent of fat mass, older adults, Geriatrics, RC952-954.6
Abstract

Xiting Wang, Li Li, Jing Cui, Mei Cheng, Meilin Liu Department of Geriatrics, Peking University First Hospital, Beijing, People’s Republic of ChinaCorrespondence: Meilin Liu, Department of Geriatrics, Peking University First Hospital, Beijing, People’s Republic of China, Email liumeilin@hotmail.comBackground: Body mass index (BMI) correlates with aspirin-induced bleeding risk. However, skeletal muscle mass (SMM) loss and fat gain commonly occur with aging, making BMI not a reasonable marker of bleeding risk in older individuals. In the present study, we aimed to investigate the prognostic value of myopenic obesity based on the percent of fat mass (%FM) for aspirin-induced bleeding in Chinese patients over 60 years old.Methods: We prospectively analyzed 185 patients taking aspirin for primary and secondary prevention of cardiovascular diseases. Body composition parameters were estimated using bioelectrical impedance analysis. We defined myopenic obesity (MO) as a height-adjusted appendicular SMM < 7.0 kg/m2 in males and < 5.7 kg/m2 in females with a %FM > 29% in males and > 41% in females or a BMI ≥ 25 kg/m2. The patients were categorized into four groups by the presence or absence of myopenia and obesity.Results: Based on the %FM grouping, the bleeding risk was significantly higher in the MO group, followed by the nonmyopenic obesity, myopenic nonobesity, and nonmyopenic nonobesity groups (P = 0.044). No statistically significant differences in the probability of bleeding events were observed among the four BMI-based groups (P = 0.502). Multivariate Cox analysis indicated that MO (hazard ratio [HR] 2.724, 95% confidence interval [CI] 1.073– 6.918, P = 0.035), aspirin dose (100 vs 50 mg/day, HR 2.609, 95% CI 1.291– 5.273, P = 0.008), concomitant use of histamine-2 receptor antagonists and proton pump inhibitors (HR 1.777, 95% CI 1.007– 3.137, P = 0.047), and hemorrhage history (HR 2.576, 95% CI 1.355– 4.897, P = 0.004) were associated with bleeding events independently.Conclusion: %FM-based MO was an independent predictor of aspirin-induced bleeding in older Chinese individuals. Reducing %FM rather than BMI should be an optimal strategy for the management of myopenic obesity.Keywords: myopenic obesity, aspirin-induced bleeding, body composition, percent of fat mass, older adults

Published
2023

22. Study on the Relationship and Predictive Value of First-Trimester Pregnancy-Associated Plasma Protein-A, Maternal Factors, and Biochemical Parameters in Gestational Diabetes Mellitus: A Large Case-Control Study in Southern China Mothers

Author

Cui J, Li P, Chen X, Li L, Ouyang L, Meng Z, and Fan J

Subjects
gestational diabetes mellitus, pregnancy-associated plasma protein-a, maternal factors, biochemical markers, predictive value., Specialties of internal medicine, RC581-951
Abstract

Jinhui Cui,&ast; Ping Li,&ast; Xinjuan Chen, Ling Li, Liping Ouyang, Zhaoran Meng, Jianhui Fan Department of Obstetrics and Gynecology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jianhui Fan, No. 600, Tianhe Road, Tianhe, Guangzhou, People’s Republic of China, Tel +86 18922102608, Email fanjh@mail.sysu.edu.cnObjective: To investigate the relationship and predictive value of first-trimester pregnancy-associated plasma protein A (PAPP-A), maternal factors, and biochemical parameters with gestational diabetes mellitus (GDM) in southern China mothers.Methods: This study recruited 4872 pregnant women. PAPP-A, the free beta subunit of human chorionic gonadotropin (free β-HCG), fasting plasma glucose (FPG), total cholesterol (TC), triglycerides (TG), and high- and low-density lipoproteins (HDL, LDL) were measured at 11– 13+ weeks of gestation. GDM was diagnosed based on a 75 g oral glucose tolerance test at 24– 28 weeks of gestation. We performed stepwise logistic regression analysis to determine the odds ratio (OR) and the 95% confidence interval (CI) of GDM. We used Receiver Operating Characteristic (ROC) curves with the area under the curve (AUC) to evaluate the predictive value of PAPP-A, maternal factors, and biochemical markers. The significance of the differences between the AUC values was assessed using the DeLong test.Results: GDM was diagnosed in 750 (15.39%) women. Independent factors for GDM were age, pre-gestational BMI, GWG before a diagnosis of GDM, previous history of GDM, family history of diabetes, FPG, TG, LDL, PAPP-A, and TC. The AUC of PAPP-A was 0.56 (95% CI 0.53– 0.58). The AUC of a model based on combined maternal factors, biochemical markers, and PAPP-A was 0.70 (95% CI 0.68– 0.72). Differences in AUC values between PAPP-A alone and the model based on combined maternal factors, biochemical markers, and PAPP-A were statistically significant (Z= 9.983, P< 0.001).Conclusion: A Low serum PAPP-A level in the first trimester is an independent risk factor for developing GDM later in pregnancy. However, it is not a good independent predictor although the predictive value of a low serum PAPP-A level increases when combined with maternal factors and biochemical markers.Keywords: gestational diabetes mellitus, pregnancy-associated plasma protein-A, maternal factors, biochemical markers, predictive value

Published
2023

23. Global Trends and Research Progress of Photodynamic Therapy in Skin Cancer: A Bibliometric Analysis and Literature Review

Author

Sun J, Zhao H, Fu L, Cui J, and Yang Y

Subjects
photodynamic therapy, photosensitizers, skin cancer, bibliometric, Dermatology, RL1-803
Abstract

Jiachen Sun,1,&ast; Hongqing Zhao,1,&ast; Lin Fu,2,&ast; Jing Cui,3,&ast; Yuguang Yang1 1Department of Dermatology, Fourth Medical Center of Chinese PLA General Hospital, Beijing, People’s Republic of China; 2Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 3Navy Clinical College, the Fifth School of Clinical Medicine, Anhui Medical University, Hefei, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Yuguang Yang, Email yangyuguang304@163.comBackground: Based on photochemical reactions through the combined use of light and photosensitizers, photodynamic therapy (PDT) is gaining popularity for the treatment of skin cancer. Various photosensitizers and treatment regimens are continuously being developed for enhancing the efficacy of PDT on skin cancer. Reviewing the development history of PDT on skin cancer, and summarizing its development direction and research status, is conducive to the further research.Methods: To evaluate the research trends and map knowledge structure, all publications covering PDT on skin cancer were retrieved and extracted from Web of Science database. We applied VOSviewer and CiteSpace softwares to evaluate and visualize the countries, institutes, authors, keywords and research trends. Literature review was performed for the analysis of the research status of PDT on skin cancer.Results: A total of 2662 publications were identified. The elements, mechanism, pros and cons, representative molecular photosensitizers, current challenges and research progress of PDT on skin cancer were reviewed and summarized.Conclusion: This study provides a comprehensive display of the field of PDT on skin cancer, which will help researchers further explore the mechanism and application of PDT more effectively and intuitively.Keywords: photodynamic therapy, photosensitizers, skin cancer, bibliometric

Published
2023

24. Bibliometric Analysis of Global Research Landscape and Hotspots on Dysmenorrhea: Where are We Now?

Author

Liu Z, Li Z, Meng Q, Gu Z, and Cui J

Subjects
bibliometric analysis, dysmenorrhea, women, pain, research hotspots, Medicine (General), R5-920
Abstract

Zhihui Liu,1,&ast; Zhuo Li,2,&ast; Qian Meng,3 Zhenpeng Gu,4 Jinxiu Cui4 1Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China; 2School of Medicine, Nankai University, Tianjin, People’s Republic of China; 3Department of Obstetrics and Gynecology, Zibo Maternal and Child Health Hospital, Zibo, People’s Republic of China; 4Department of Obstetrics and Gynecology, Binzhou Medical University Hospital, Binzhou, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jinxiu Cui, Department of Obstetrics and Gynecology, Binzhou Medical University Hospital, No. 661 Huanghe 2nd Road, Binzhou, Shandong Province, 256603, People’s Republic of China, Email doctorcuijx@126.comPurpose: Dysmenorrhea is the most common gynecological condition among women of childbearing age and remains a challenging public health issue. This study aimed to visualize profiles and hotspots in dysmenorrhea research through a bibliometric analysis to deepen the understanding of knowledge in this field.Methods: Articles and reviews on dysmenorrhea published from 2000 to 2021 were collected. We summarized standard bibliometric indicators. Publications were systematically assessed in terms of country, institution, author, journal, reference, and keywords using Citespace, VOSviewer, Bibliometric, and an online platform. Besides, correlation analyses of country-specific characteristics and bibliometric indicators were performed.Results: 3407 publications were included. Dysmenorrhea-related publications have been increasing steadily annually. China and the United States were the most productive and academically influential countries, respectively. Correlation analysis revealed that economic power is an essential factor influencing scientific activity. However, collaboration in dysmenorrhea research remained weak. Natl Yang Ming Univ and Vercellini P were the most productive institution and influential author, respectively. A significant proportion of dysmenorrhea research was published in high-impact journals and it was explored at a multidisciplinary level. Current research topics focus on two primary areas: (1) pathophysiology, such as pathogenesis, oxidative stress, and functional connectivity, and (2) public health impacts, such as quality of life, burden, depression, and exercise.Conclusion: Dysmenorrhea research has received extensive attention from scholars and is rapidly evolving. Improved collaboration and interdisciplinary exploration may advance this field. Public health research and pathophysiological exploration of dysmenorrhea are current research hotspots and may also be a focus of research in the coming years.Keywords: bibliometric analysis, dysmenorrhea, women, pain, research hotspots

Published
2023

25. Effect of Alcohol Intake on Inflammatory Status and Prognosis in Cancer Patients

Author

Liu X, Zhang W, Ji W, Zheng K, Zhao Y, He Y, Cui J, and Li W

Subjects
alcohol, inflammation, cancer, prognosis, Pathology, RB1-214, Therapeutics. Pharmacology, RM1-950
Abstract

Xiangliang Liu,1,&ast; Wenxin Zhang,2,&ast; Wei Ji,1,&ast; Kaiwen Zheng,1 Yixin Zhao,1 Yuwei He,1 Jiuwei Cui,1 Wei Li1 1The First Hospital of Jilin University, Changchun, People’s Republic of China; 2Zhongnan Hospital, Wuhan University, Wuhan, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jiuwei Cui; Wei Li, Jilin University, Xinmin St No. 126, Changchun, 130021, People’s Republic of China, Tel +8613844095420 ; +8613206282295, Fax +86 431-85619254, Email cuijw@jlu.edu.cn; liwei66@jlu.edu.cnPurpose: To explore the effect of alcohol on the inflammatory status and prognosis of patients with malignancy.Patients and Methods: The clinical data of patients with malignant tumor who were admitted to the First Hospital of Jilin University from November 2011 to December 2018 were collected including basic clinical information, anthropometric indicators, body composition analysis, and serological indicators. Univariate and multivariate Cox proportional hazards models were performed to find predictors of survival. A nomogram was generated to indicate the interrelationships between the variables in the prediction model and the extent to which alcohol consumption affects prognosis. The C-index and calibration curves were used to verify the predictive accuracy of the scoring system.Results: A total of 2929 cancer patients were included in this study, of which 552 (18.8%) patients had alcohol consumption habits and 2377 (81.2%) patients had no alcohol history. Patients in the Alcohol group had significantly shorter overall survival (OS) than the Non-Alcohol group, and further sub-analysis indicated alcohol consumption was significantly associated with prognosis of advanced breast cancer (HR = 4.617, 95% CI 1.361– 15.664, p=0.014), and early stage hepatocellular carcinoma (HCC) without viral hepatitis (HR = 8.933, 95% CI 1.444– 55.275, p = 0.019). Multivariate Cox regression models also demonstrated that daily alcohol intake was a risk factor of survival benefits (HR = 1.256, 95% CI 1.016– 1.554, p = 0.036). Finally, a nomogram was constructed and the c-index of this scoring system is 0.751. The 3- and 5-year calibration curves of the model show a high agreement between the predicted probability and the actual observed survival rate.Conclusion: Alcohol intake was demonstrated associates with patient outcomes. A human component-prognosis scoring system was established to predict the survival benefits of cancer patients.Keywords: alcohol, inflammation, cancer, prognosis

Published
2022

26. Effect of AMPK Subunit Alpha 2 Polymorphisms on Postherpetic Pain Susceptibility in Southwestern Han Chinese

Author

Mei Y, Mu Y, Wang W, Tan BT, Chen YH, Li YP, Zhu D, Li W, Cui J, and Yu LH

Subjects
ampk, prkaa2, polymorphism, postherpetic neuralgia, Medicine (General), R5-920
Abstract

Yang Mei,1,2 Yang Mu,3 Win Wang,2 Bo-Tao Tan,1 Yao-Hua Chen,4 Yu-Ping Li,4 Dan Zhu,4 Wei Li,2 Jian Cui,4 Le-Hua Yu1 1Department of Rehabilitation Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China; 2Department of Pain Medicine, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, People’s Republic of China; 3Department of Rehabilitation Medicine, Chongqing University Fuling Hospital, Chongqing, People’s Republic of China; 4Department of Pain Medicine, Southwest Hospital, Army Medical University, Chongqing, People’s Republic of ChinaCorrespondence: Jian Cui; Le-Hua Yu, Email cqjian211@163.com; 300895@cqmu.edu.cnIntroduction: Adenosine 5’-monophosphate (AMP)-activated protein kinase (AMPK) can influence energy metabolism. Energy metabolism imbalance is closely associated with the occurrence of neuropathic pain (NeP). Rs10789038 and rs2796498 are genetic polymorphisms of PRKAA2, the gene encoding AMPK, which is closely related to energy metabolism imbalance. This study aimed to explore the relationship between PRKAA2 and postherpetic neuralgia (PHN) in the southwestern Chinese Han population.Methods: This study enrolled 132 PHN patients and 118 healthy subjects. The rs10789038 and rs2796498 PRKAA2 genotypes were identified in all participants. The association between these single nucleotide polymorphisms and PHN susceptibility was evaluated in the dominant and recessive models. Haplotype analysis of patients with PHN and healthy controls was performed.Results: The PHN patients were older than the healthy subjects (P < 0.05); however, the other clinical characteristics between two groups were not significantly different (all P > 0.05). Genotypes and allele frequencies differed significantly between PHN patients and healthy subjects in the rs10789038 polymorphism (P < 0.05), but not in rs2796498 (P > 0.05). In addition, the GG haplotype of rs10789038-rs2796498 correlated negatively with PHN occurrence in haplotype analysis (P < 0.05).Conclusion: PHN occurrence may be related to the PRKAA2 rs10789038 A>G genetic polymorphism in the southwestern Chinese Han population.Keywords: AMPK, PRKAA2, polymorphism, postherpetic neuralgia

Published
2022

27. Elevated Blood Glucose is Associated with Severe Exacerbation of Chronic Obstructive Pulmonary Disease

Author

Chen G, Lin Q, Zhuo D, and Cui J

Subjects
blood glucose, hba1c, copd, severe exacerbation, Diseases of the respiratory system, RC705-779
Abstract

Guohuan Chen, Qingyu Lin, Debin Zhuo, Jinhe Cui Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Putian University, Putian, People’s Republic of ChinaCorrespondence: Guohuan Chen, Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Putian University, 999 Dongzhen East Road, Licheng District, Putian City, 351100, Fujian Province, People’s Republic of China, Tel +86-594-2730387, Email chenguohuanpt@163.comBackground: To evaluate the association of elevated blood glucose with the risk of acute exacerbations in patients with chronic obstructive pulmonary disease (COPD).Methods: Totally 526 consecutive patients with COPD recruited between Jan. 2018 and July 2019 were included in this study. Based on the American Diabetes Association’s Standards of Care, these patients were divided into three groups according to HbA1c level: low HbA1c level (HbA1c < 5.7%, n=204), moderate HbA1c level (HbA1c 5.7– 6.4%, n=165), and high HbA1c level (HbA1c ≥ 6.5%, n=157). All subjects were followed up for 18 months. Multivariate Cox regression analysis was used to evaluate the predicting value of HbA1c for the time of the next COPD severe exacerbation.Results: Totally 141 (26.8%) patients in the study had at least 1 severe exacerbation. The proportion of patients suffering from at least 1 severe exacerbation was significantly higher (P< 0.01) for patients with high (36.3%) and moderate HbA1c levels (25.5%) compared to those with low HbA1c levels (20.6%). Multivariate Cox regression analysis indicated that high (HR=2.74, 95% CI: 1.70– 4.41; P< 0.01) and moderate HbA1c levels (HR=2.19, 95% CI: 1.39– 3.46; P< 0.01) were significantly associated with a higher risk of the next severe exacerbation compared with low HbA1c level, after controlling for potential confounders including age, gender, body mass index (BMI), smoking status, disease duration of COPD, frequency of hospitalization due to acute exacerbation of COPD (AECOPD) in the past 12 months, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages, COPD assessment test (CAT) score, corticosteroids use, hypertension, and cardiovascular diseases. Subgroup analyses also indicated a significant association between HbA1c levels and risk of the next severe exacerbation in different GOLD stages and diabetes status.Conclusion: Elevated blood glucose, no matter with or without diabetes, is significantly associated with a higher risk of the next severe exacerbation for patients with COPD.Keywords: blood glucose, HbA1c, COPD, severe exacerbation

Published
2022

28. New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism

Author

Wumaier K, Li W, and Cui J

Subjects
new oral anticoagulants, low molecular weight heparin, venous thromboembolism, cancer-associated thrombosis, anticoagulants, Therapeutics. Pharmacology, RM1-950
Abstract

Kaidireyahan Wumaier,1 Wenqian Li,1 Jiuwei Cui2 1The First Hospital of Jilin University, Jilin University, Changchun, People’s Republic of China; 2Department of Cancer Center, the First Hospital of Jilin University, Changchun, People’s Republic of ChinaCorrespondence: Jiuwei Cui, Department of Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, 130021, People’s Republic of China, Tel/Fax +86-0431-88782178, Email cuijw@jlu.edu.cnAbstract: Venous thromboembolism (VTE) is associated with increased morbidity and mortality, decreased quality of life, and higher economic burden in patients with cancer. Currently, the treatment of VTE in patients with cancer is particularly challenging. For many years, low molecular weight heparin (LMWHs) has been the standard for the treatment of cancer-associated VTE. Recently, the introduction of new oral anticoagulants (NOACs) may offer an oral anticoagulant option for some patients with cancer-associated thrombosis (CAT) as a growing body of literature supports the use of NOACs in the setting of CAT. With the use of NOAC as a new option in the management of CAT, clinicians now face several choices for the individual cancer patient with VTE. We need a more in-depth understanding of the drug properties, efficacy and safety, economic analysis that allows us to choose the most appropriate treatment for each patient. In the review, we will present an overview of CAT management, discuss the available evidence, economic costs for NOACs in the treatment of CAT, and seek to provide the best range of treatments for cancer patients.Keywords: new oral anticoagulants, low molecular weight heparin, venous thromboembolism, cancer-associated thrombosis, anticoagulants

Published
2022

29. Compassionate Use of Contezolid for the Treatment of Tuberculous Pleurisy in a Patient with a Leadless Pacemaker

Author

Kang Y, Ge C, Zhang H, Liu S, Guo H, and Cui J

Subjects
contezolid, tuberculous pleurisy., Infectious and parasitic diseases, RC109-216
Abstract

Yixin Kang,1,&ast; Cheng Ge,2,&ast; Huan Zhang,3 Saizhe Liu,4 Hongyang Guo,4 Junchang Cui1 1Department of Respiratory Diseases, the First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, 100853, People’s Republic of China; 2Department of Cardiology, the First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, 100853, People’s Republic of China; 3Center of Medicine Clinical Research, the First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, 100853, People’s Republic of China; 4Department of Cardiology, the Sixth Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, 100853, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Hongyang Guo; Junchang Cui, The First Medical Center, Chinese People’s Liberation Army General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, People’s Republic of China, Email guohongyang301@126.com; guoguoyoumeng@163.comAbstract: We report the case of an 87-year-old woman with tuberculous pleurisy. She developed adverse effects in the form of thrombocytopenia and gastrointestinal hemorrhage with isoniazid, and thrombocytopenia with linezolid. Her treatment was switched to contezolid plus cycloserine for a 4-week antibiotic duration, with a favorable outcome.Keywords: contezolid, tuberculous pleurisy

Published
2022

30. Association Between Serum Asprosin and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus in the Community: A Cross-Sectional Study

Author

Xu L, Cui J, Li M, Wu Q, Liu M, Xu M, Shi G, Yin J, and Yang J

Subjects
asprosin, type 2 diabetes mellitus, diabetic nephropathies, creatinine, albuminuria, logistic models, community health services, Specialties of internal medicine, RC581-951
Abstract

Linxin Xu,1,2,&ast; Junfang Cui,3,&ast; Mina Li,2 Qianqian Wu,2 Ming Liu,2 Minggang Xu,4 Guoliang Shi,4 Jianhong Yin,2 Jing Yang1,2 1First Clinical Medical College, Shanxi Medical University, Taiyuan, People’s Republic of China; 2Department of Endocrinology, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China; 3Department of Geratology, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, People’s Republic of China; 4Department of Endocrinology, Changzhi Second People’s Hospital, Changzhi, 046000, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jing Yang; Jianhong Yin, Tel +86-351-4639756, Email yangjlm@126.com; yinjianhong0351@163.comObjective: To explore the association between serum asprosin and diabetic nephropathy (DN) in patients with type 2 diabetes mellitus (T2DM) in the community.Methods: In this cross-sectional study, we retrospectively collected the clinical data of T2DM patients from a community health service center in southeastern Shanxi Province between November 2019 and July 2021. Logistic regression analysis was used to calculate the odds ratio (OR) and the 95% confidence interval (95% CI) of asprosin levels on the risk of DN.Results: Among 498 T2DM patients included in this study, 221 had microalbuminuria, 105 had massive albuminuria, and 172 did not have any signs of nephropathy. Serum asprosin level was positively correlated with diastolic blood pressure, body mass index, triglycerides, aspartate aminotransferase, alanine aminotransferase, creatinine, ACR and albumin-to-creatinine ratio (all P < 0.05) and negatively correlated with low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, fasting plasma glucose, HbA1c and estimated glomerular filtration rate (all P < 0.05). After adjusting for covariates, increased asprosin was associated with diabetic nephropathy (all OR = 2.560, 95% CI: 1.1592– 4.116; P < 0.001).Conclusion: The risk of DN significantly increases with serum asprosin levels, especially among female patients.Keywords: asprosin, type 2 diabetes mellitus, diabetic nephropathies, creatinine, albuminuria, logistic models, community health services

Published
2022

31. A Predictive Model for Qualitative Evaluation of PG-SGA in Tumor Patients Through Machine Learning

Author

Liu X, Li Y, Ji W, Zheng K, Lu J, Zhao Y, Zhang W, Liu M, Cui J, and Li W

Subjects
nutritional assessment, machine learning, pg-sga, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Xiangliang Liu,1,&ast; Yuguang Li,2,&ast; Wei Ji,1,&ast; Kaiwen Zheng,1 Jin Lu,1 Yixin Zhao,1 Wenxin Zhang,3 Mingyang Liu,2 Jiuwei Cui,1 Wei Li1 1Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, People’s Republic of China; 2College of Instrumentation and Electrical Engineering, Jilin University, Changchun, Jilin, People’s Republic of China; 3Department of Cancer Radiotherapy and Chemotherapy, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Mingyang Liu, College of Instrumentation and Electrical Engineering, Jilin University, Ximinzhu St No. 938, Changchun, Jilin, People’s Republic of China, Tel +8615504318027, Email liumingyang@jlu.edu.cn Wei Li, Cancer center, The First Hospital of Jilin University, Xinmin St No. 1, Changchun, Jilin, People’s Republic of China, Tel +8613206282295, Fax +86 431-85619254, Email liwei66@jlu.edu.cnObjective: Patient-Generated Subjective Global Assessment (PG-SGA) was a nutritional status assessment technique specifically tailored for patients with oncology. The goal of this study was to develop a machine learning (ML) prediction model for predicting PG-SGA categorization of patients with tumor.Methods: From 2014 to 2020, patients at the First Hospital of Jilin University performed laboratory testing, bioelectrical impedance, physical measures, and the PG-SGA scale. A total of 8230 patients were involved in the study. Patients with missing or partial data were removed, leaving 7287 patients, of which 3743 were males and 3544 were females. ML was used to design a clinical prediction model for PG-SGA categories.Results: Through the least absolute shrinkage and selection operator (LASSO) and the correlation matrix, 135 variables were screened and 6 variables were retained; ML was performed among the remaining variables. The accuracy of neural network prediction models was 70.3% and 70.4% for males and females in the training cohort, respectively, and 74.4% and 73.2% for males and females in the validation cohort, respectively. The area under curve (AUC) of males was 0.87 for PG-SGA scores “ 0– 3”, 0.70 for PG-SGA scores “ 4– 8” and 0.74 for PG-SGA scores “> 8”. As for females, the AUC was 0.85 for PG-SGA scores “ 0– 3”, 0.65 for PG-SGA scores “ 4– 8” and 0.76 for PG-SGA scores “> 8”. The results of confusion matrix showed that the models were of good predictive validity. The prediction model was nearly 90% accurate for predictions that do not require nutritional support.Conclusion: We demonstrated that neural network learning is the best clinical prediction model using ML. The model can work as a prediction for the PG-SGA classification of patients with cancer and can be promoted further in the clinic.Keywords: nutritional assessment, machine learning, PG-SGA

Published
2022

32. Fluorescent Imaging-Guided Chemo- and Photodynamic Therapy of Hepatocellular Carcinoma with HCPT@NMOFs-RGD Nanocomposites

Author

Shang Y, Zhang H, Cheng Y, Cao P, Cui J, Yin X, Fan S, and Li Y

Subjects
zirconium porphyrin metal-organic frameworks, 10-hydroxycamptothecin, hepatocellular carcinoma, chemotherapy, photodynamic therapy, Medicine (General), R5-920
Abstract

Yue Shang,1,&ast; Hui Zhang,2,&ast; Yajia Cheng,3 Peipei Cao,3 Jianlin Cui,3 Xuebo Yin,4 Saijun Fan,1 Yuhao Li5 1Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People’s Republic of China; 2Shanghai Institute of Quality Inspection and Technical Research, Shanghai, People’s Republic of China; 3Department of Pathology, Nankai University School of Medicine, Tianjin, People’s Republic of China; 4College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, People’s Republic of China; 5Beijing Geriatric Medical Research Center, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Yuhao Li, Xuanwu Hospital, Capital Medical University, Beijing, 100053, People’s Republic of China, Tel +86-10-83198269, Email liyuhao@xwh.ccmu.edu.cnBackground: Hepatocellular carcinoma (HCC), arising from hepatocytes, is the most common primary liver cancer. It is urgent to develop novel therapeutic approaches to improve the grim prognosis of advanced HCC. 10-hydroxycamptothecin (HCPT) has good antitumor activity in cells; however, its hydrophobicity limits its application in the chemotherapy of HCC. Recently, nanoscale porphyrin metal-organic frameworks have been used as drug carriers due to their low biotoxicity and photodynamic properties.Methods: Nanoscale zirconium porphyrin metal-organic frameworks (NMOFs) were coated with arginine-glycine-aspartic acid (RGD) peptide to prepare NMOFs-RGD first. The HepG2 cell line, zebrafish embryos and larvae were used to test the biotoxicity and fluorescence imaging capability of NMOFs-RGD both in vitro and in vivo. Then, NMOFs were used as the skeleton, HCPT was assembled into the pores of NMOFs, while RGD peptide was wrapped around to synthesize a novel kind of nanocomposites, HCPT@NMOFs-RGD. The tissue distribution and chemo- and photodynamic therapeutic effects of HCPT@NMOFs-RGD were evaluated in a doxycycline-induced zebrafish HCC model and xenograft mouse model.Results: NMOFs-RGD had low biotoxicity, good biocompatibility and excellent imaging capability. In HCC-bearing zebrafish, HCPT@NMOFs-RGD were specifically enriched in the tumor by binding specifically to integrin αvβ3 and led to a reduction in tumor volume. Moreover, the xenografts in mice were eliminated remarkably following HCPT@NMOFs-RGD treatment with laser irradiation, while little morphological change was found in other main organs.Conclusion: The nanocomposites HCPT@NMOFs-RGD accomplish tumor targeting and play synergistic chemo- and photodynamic therapeutic effects on HCC, offering a novel imaging-guided drug delivery and theranostic platform.Keywords: zirconium porphyrin metal-organic frameworks, 10-hydroxycamptothecin, hepatocellular carcinoma, chemotherapy, photodynamic therapy

Published
2022

33. The Effect of SOCS2 Polymorphisms on Type 2 Diabetes Mellitus Susceptibility and Diabetic Complications in the Chinese Han Population

Author

Pan J, Tong R, Deng Q, Tian Y, Wang N, Peng Y, Fei S, Zhang W, Cui J, Guo C, Yao J, Wei C, and Xu J

Subjects
type 2 diabetes mellitus, socs2 variants, diabetic complications, life style, Therapeutics. Pharmacology, RM1-950
Abstract

Juan Pan,1,2,&ast; Rui Tong,1,&ast; Qing Deng,3 Yanni Tian,1 Ning Wang,1 Yanqi Peng,1 Sijia Fei,1 Wei Zhang,4 Jiaqi Cui,1 Chaoying Guo,1 Juanchuan Yao,1 Cui Wei,1 Jing Xu1 1Department of Geriatric Endocrinology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, Shaanxi, People’s Republic of China; 2Department of Endocrinology, Xianyang Central Hospital, Xianyang, 712000, Shaanxi, People’s Republic of China; 3Department of Endocrinology, No. 215 Hospital of Shaanxi Nuclear Industry, Xianyang, 712000, Shaanxi, People’s Republic of China; 4Department of Breast Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, Shaanxi, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Cui Wei; Jing XuDepartment of Geriatric Endocrinology, The First Affiliated Hospital of Xi’an Jiaotong University, #277 West Yanta Road, Xi’an, 710061, Shaanxi, People’s Republic of China, Tel +86 18991232462; Tel +86 18991232462Email doctorweiwei.cui@126.com; 254309205@qq.comBackground: SOCS2 is downregulated in diabetes, which might be related to diabetes. We explored the effect of SOCS2 polymorphisms on the development of type 2 diabetes mellitus (T2DM) and diabetic complications.Methods: The subjects consisted of 500 patients with T2DM and 501 healthy controls. Five variants in SOCS2 were genotyped by Agena MassARRAY system. RT-qPCR profiling was performed to detect the expression of SOCS2 mRNA. Logistic regression analysis was utilized to calculate odds ratio (OR) and 95% confidence intervals (95% CIs).Results: Rs3825199 (OR = 1.44, p = 0.007), rs11107116 (OR = 1.39, p = 0.014) and rs10492321 (OR = 1.48, p = 0.004) had an increased T2DM risk of T2DM. Moreover, the contribution of SOCS2 polymorphisms to T2DM risk was associated with age, gender, smoking, drinking, and BMI. SOCS2 variants also had a reduced risk for T2DM patients with diabetic nephropathy, diabetic retinopathy and coronary heart disease. SOCS2 rs10492321 was the best single locus model. SOCS2 mRNA was downregulated in patients with T2DM compared to healthy controls (p = 0.029).Conclusion: This study firstly reported that rs3825199, rs11107116 and rs10492321 in SOCS2 conferred to an increased risk for the occurrence of T2DM in the Chinese Han population. Moreover, SOCS2 mRNA was downregulated in patients with T2DM, suggesting that SOCS2 might have an important role in the occurrence of T2DM.Keywords: type 2 diabetes mellitus, SOCS2 variants, diabetic complications, life style

Published
2022

34. Relationship Between KCNQ1 Polymorphism and Type 2 Diabetes Risk in Northwestern China

Author

Xu J, Zhang W, Song W, Cui J, Tian Y, Chen H, Huang P, Yang S, Wang L, He X, Shi B, and Cui W

Subjects
kcnq1, polymorphism, type 2 diabetes, case-control strategy, mdr analysis, Therapeutics. Pharmacology, RM1-950
Abstract

Jing Xu,1 Wei Zhang,2 Wei Song,1 Jiaqi Cui,1 Yanni Tian,1 Huan Chen,1 Pan Huang,1 Shujun Yang,1 Lu Wang,1 Xin He,3 Lin Wang,4 Bingyin Shi,5 Wei Cui1 1Department of Endocrinology and Second Department of Geriatrics, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, 710061, People’s Republic of China; 2Department of Breast Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, 710061, People’s Republic of China; 3Department of Endocrinology, Xi’an Aerospace General Hospital, Xi’an, Shaanxi, 710000, People’s Republic of China; 4Department of Endocrinology, Xi’an Gaoxin Hospital, Xi’an, Shaanxi, 710075, People’s Republic of China; 5Department of Endocrinology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, 710061, People’s Republic of ChinaCorrespondence: Wei CuiThe First Affiliated Hospital of Xi’an Jiaotong University, #277 Yanta West Road, Xi’an, 710061, Shaanxi, People’s Republic of ChinaEmail doctorweiwei.cui@126.comBingyin ShiThe First Affiliated Hospital of Xi’an Jiaotong University, #277 Yanta West Road, Xi’an, Shaanxi, 710061, People’s Republic of ChinaEmail xjtougao@126.comPurpose: This study aimed to explore the relationship between KCNQ1 polymorphism and type 2 diabetes mellitus (T2DM) risk in the population of Northwest China.Patients and Methods: Case-control strategy was used to reveal the correlation between KCNQ1 polymorphism and T2DM risk, and MDR analysis clarified the influence of KCNQ1 polymorphism interaction on T2DM risk. The related proteins, functions, and signal pathways of KCNQ1 were further explored through bioinformatics methods. PCR was used to explore the relative expression of KCNQ1 in T2DM patients and the controls.Results: Studies showed that rs163177, rs163184, rs2237895 and rs2283228 on the KCNQ1 gene are closely related to the risk of T2DM in Northwest China. MDR results showed that the three-locus model is the best model for T2DM risk assessment, which increases the risk of T2DM. The bioinformatics results showed that KCNQ1 closely-acted proteins are mainly involved in signal pathways such as gastric acid secretion and renin secretion. The PCR results showed that, compared with the controls, the expression of KCNQ1 was up-regulated in T2DM patients.Conclusion: The results revealed that KCNQ1 polymorphism is related to the risk of T2DM in the population of Northwest China and provide a scientific basis for the early screening and prevention of T2DM high-risk populations.Keywords: KCNQ1, polymorphism, type 2 diabetes, case-control strategy, MDR analysis

Published
2021

35. The Efficacy of Different Inflammatory Markers for the Prognosis of Patients with Malignant Tumors

Author

Zheng K, Liu X, Ji W, Lu J, Cui J, and Li W

Subjects
cancer, inflammatory markers, nutritional status, overall survival, Pathology, RB1-214, Therapeutics. Pharmacology, RM1-950
Abstract

Kaiwen Zheng &ast;, Xiangliang Liu &ast;, Wei Ji &ast;, Jin Lu, Jiuwei Cui, Wei Li Cancer Center, the First Hospital of JiLin University, Changchun, Jilin, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jiuwei Cui; Wei Li Email cuijw@jlu.edu.cn; liwei66@jlu.edu.cnBackground: Inflammation is considered essential in cancer progression, as it affects the nutritional status and prognosis of patients. In this study, we aim to analyze the efficacy of various inflammatory markers in predicting prognosis in cancer patients.Methods: Patients with malignant tumor were included as primary and validation cohort. Basic clinical information, anthropometric indicators, body composition analysis, and serological indicators were recorded. After proposing the optimal thresholds by time-dependent receiver operating characteristic (ROC), univariate and multivariate Cox regression analyses were performed to analyze the association between inflammatory markers and overall survival (OS). A nomogram was established to develop a scored-inflammatory marker system. Eight inflammatory models based on combinations of inflammatory markers were assessed. Cox regression analysis was used to analyze the relationship of each inflammatory model and mortality of participants. Then, subanalysis of specific tumor types was conducted by Cox regression. Logistic regression models were used to analyze the relationship between different inflammatory models and malnutrition.Results: Univariate and multivariate Cox regression analyses indicated that pack-years of cigarette smoking, C-reactive protein (CRP), and systemic immune-inflammation index (SII) were related to the OS of cancer patients. A nomogram was constructed to develop a scored-inflammatory marker system. Among the eight inflammatory models, patients in model A had worst prognosis compared with patients in other models. Subanalysis next showed lung cancer, breast cancer and digestive system neoplasms patients in model A suffered the worst prognosis. Logistic regression indicated that model A was also with predictive value for malnutrition.Conclusion: A scored-inflammatory marker system was established to predict the OS of cancer patients. The inflammatory models established in this study can be used to predict prognosis, as well as cancer-related malnutrition. Inflammatory model A suffered the worst OS and was with the predictive efficacy for malnutrition.Keywords: cancer, inflammatory markers, nutritional status, overall survival

Published
2021

36. LncRNA NEAT1 Acts as an miR-148b-3p Sponge to Regulate ROCK1 Inhibition of Retinoblastoma Growth

Author

Lu H, Zhang Z, Lu Y, Xiu WW, and Cui J

Subjects
lncrna neat1, mir-148b-3p, rock1, retinoblastoma, proliferation, invasion, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Hang Lu,1,&ast; Zhenjun Zhang,2,&ast; Yao Lu,3 Weiwei Xiu,1 Jinglin Cui1 1Research Center of Ophthalmology, The First Hospital of Qiqihar, Affiliated Qiqihar Hospital, Southern Medical University, Qiqihar, Heilongjiang Province, People’s Republic of China; 2Ophthalmology Department, Beiman Hongpeng Hospital of Qiqihar, Qiqihar, Heilongjiang Province, People’s Republic of China; 3International Education College, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang Province, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jinglin CuiResearch Center of Ophthalmology, The First Hospital of Qiqihar, Affiliated Qiqihar Hospital, Southern Medical University, No. 30 Gongyuan Road, Longsha District, Qiqihar, Heilongjiang Province, People’s Republic of ChinaEmail cjl35@qqhrdyyy.com.cnBackground: It is reported that long non-coding RNA nuclear paraspeckle assembly transcript 1 (LncRNA NEAT1) is involved in the occurrence and development of various cancers. However, the detailed biological function and mechanism of LncRNA NEAT1 in retinoblastoma are still unclear. So we will explore the biological function and possible mechanism of LncRNA NEAT1 in retinoblastoma.Materials and Methods: Quantitative real-time PCR (qRT-PCR) was used to detect LncRNA NEAT1 in retinoblastoma tissues and cell lines. Cell counting kit 8, Transwell and flow cytometry were applied to explore cell proliferation, invasion and apoptosis. The target miRNAs (miR) of LncRNA NEAT1 and miR and downstream target genes were predicted using Starbase3.0 software and confirmed by double luciferase reporting test and RNA binding protein immunoprecipitation (RIP). Western Blot was applied to explore ROCK1 in cells, and tumor allogeneic experiment was applied to study the role of LncRNA NEAT1 on tumor growth.Results: It was found that LncRNA NEAT1 was up-regulated in retinoblastoma tissues, cells and serum, and the prognosis of patients with high expression of LNC RNA NEAT 1 was poor. Functional analysis showed that knocking down LncRNA NEAT1 could weaken proliferation and invasion, and accelerate apoptosis. Tumor allogeneic experiment showed that sh-NEAT1 injection can inhibit tumor growth. In addition, LncRNA NEAT1 inhibited proliferation and invasion, and promoted apoptosis through miR-148b-3p/ROCK1 axis.Conclusion: LncRNA NEAT1 can mediate miR-148b-3p/ROCK1 axis to weaken the proliferation and invasion of retinoblastoma.Keywords: LncRNA NEAT1, miR-148b-3p, ROCK1, retinoblastoma, proliferation, invasion

Published
2021

37. Study of the decay $D^0\rightarrow \rho(770)^-e^+\nu_e$

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., An, Q., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chai, X. Y., Chang, J. F., Che, G. R., Che, Y. Z., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Chen, Z. Y., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, L., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, X. T., Huang, Y. P., Huang, Y. S., Hussain, T., Hölzken, F., Hüsken, N., der Wiesche, N. in, Jackson, J., Janchiv, S., Jeong, J. H., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., Kühn, W., Lane, J. J., Lavezzi, L., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, K., Li, K. L., Li, L. J., Li, L. K., Li, Lei, Li, M. H., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, S. X., Li, T., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Y., Li, X. Z., Li, Y. G., Li, Z. J., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, Y. P., Libby, J., Limphirat, A., Lin, C. C., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F., Liu, F. H., Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. H., Liu, H. M., Liu, Huihui, Liu, J. B., Liu, J. Y., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, X. L., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, J. R., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, L. R., Ma, M. M., Ma, Q. M., Ma, R. Q., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y. M., Maas, F. E., MacKay, I., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pathak, A., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H., Qi, H. R., Qi, M., Qi, T. Y., Qian, S., Qian, W. B., Qiao, C. F., Qiao, X. K., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. P., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, M. Q., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J., Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, H. C., Shi, J. L., Shi, J. Y., Shi, Q. Q., Shi, S. Y., Shi, X., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, S. S, Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, W. Y., Sun, Y., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tao, Q. T., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, B. L., Wang, Bo, Wang, D. Y., Wang, F., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, M., Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wang, Ziyi, Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, X., Wu, X. H., Wu, Y., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, S. Y., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, H. Y., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W., Xu, W. L., Xu, X. P., Xu, Y., Xu, Y. C., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, T., Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, J. H., Yin, Junhao, You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, M. C., Yu, T., Yu, X. D., Yu, Y. C., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Z. Y., Yue, C. X., Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q. Y., Zhang, R. Y., Zhang, S. H., Zhang, Shulei, Zhang, X. M., Zhang, X. Y, Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. Y., Zhang, Z. Z., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, L., Zhao, Lei, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, H., Zhou, J. Y., Zhou, L. P., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhou, Z. C., Zhu, A. N., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, T. J., Zhu, W. D., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment
Abstract

We present a study of the semileptonic decay $D^0\rightarrow \pi^-\pi^0e^{+}\nu_{e}$ using an $e^+e^-$ annihilation data sample of $7.93~\mathrm{fb}^{-1}$ collected at the center-of-mass energy of 3.773 GeV with the BESIII detector. The branching fraction of $D^0\to \rho(770)^-e^+\nu_e$ is measured to be $(1.439 \pm 0.033(\rm stat.) \pm 0.027(\rm syst.)) \times10^{-3}$, which is a factor 1.6 more precise than previous measurements. By performing an amplitude analysis, we measure the hadronic form-factor ratios of $D^0\to \rho(770)^-e^+\nu_e$ at $q^2=0$ assuming the single-pole-dominance parametrization: $r_{V}=V(0)/A_1(0)=1.548\pm0.079(\rm stat.)\pm0.041(\rm syst.)$ and $r_{2}=A_2(0)/A_1(0)=0.823\pm0.056(\rm stat.)\pm0.026(\rm syst.)$., Comment: 12 pages, 3 figures

Published
2024

38. Searching for the massless dark photon in $c\to u\gamma'$

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chai, X. Y., Chang, J. F., Che, G. R., Che, Y. Z., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Chen, Z. Y., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, L., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, Q. P., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, X. T., Huang, Y. P., Huang, Y. S., Hussain, T., Hölzken, F., Hüsken, N., der Wiesche, N. in, Jackson, J., Janchiv, S., Jeong, J. H., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., Kühn, W., Lavezzi, L., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, K., Li, K. L., Li, L. J., Li, L. K., Li, Lei, Li, M. H., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, S. X., Li, T., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Y., Li, X. Z., Li, Y. G., Li, Z. J., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, Y. P., Libby, J., Limphirat, A., Lin, C. C., Lin, C. X., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F., Liu, F. H., Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. H., Liu, H. M., Liu, Huihui, Liu, J. B., Liu, J. Y., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, X. L., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, J. R., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, L. R., Ma, M. M., Ma, Q. M., Ma, R. Q., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y. M., Maas, F. E., MacKay, I., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pathak, A., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H., Qi, H. R., Qi, M., Qi, T. Y., Qian, S., Qian, W. B., Qiao, C. F., Qiao, X. K., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. P., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, M. Q., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J., Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, H. C., Shi, J. L., Shi, J. Y., Shi, Q. Q., Shi, S. Y., Shi, X., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, S. S, Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, W. Y., Sun, Y., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tao, Q. T., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, B. L., Wang, Bo, Wang, D. Y., Wang, F., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, M., Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. H., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wang, Ziyi, Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, X., Wu, X. H., Wu, Y., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, S. Y., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, H. Y., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W., Xu, W. L., Xu, X. P., Xu, Y., Xu, Y. C., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, J. H., Yang, T., Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, J. H., Yin, Junhao, You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, M. C., Yu, T., Yu, X. D., Yu, Y. C., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Z. Y., Yue, C. X., Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q. Y., Zhang, R. Y., Zhang, S. H., Zhang, Shulei, Zhang, X. M., Zhang, X. Y, Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. Y., Zhang, Z. Z., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, L., Zhao, Lei, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, H., Zhou, J. Y., Zhou, L. P., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhou, Z. C., Zhu, A. N., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, T. J., Zhu, W. D., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment
Abstract

In the effective field theory, the massless dark photon $\gamma'$ can only couple with the Standard Model particle through operators of dimension higher than four, thereby offering a high sensitivity to the new physics energy scale. Using $7.9~\rm{fb^{-1}}$ of $e^+e^-$ collision data collected at $\sqrt{s}=3.773$ GeV with the BESIII detector at the BEPCII collider, we measure the effective flavor-changing neutral current coupling of $cu\gamma'$ in $D^0\to\omega\gamma'$ and $D^0\to\gamma\gamma'$ processes to search for the massless dark photon. No significant signals are observed, and the upper limits at the 90% confidence level on the massless dark photon branching fraction are set to be $1.1\times10^{-5}$ and $2.0\times10^{-6}$ for $D^0\to\omega\gamma'$ and $D^0\to\gamma\gamma'$, respectively. These results provide the most stringent constraint on the new physics energy scale associated with $cu\gamma'$ coupling in the world, with the new physics energy scale related parameter $|\mathbb{C}|^2+|\mathbb{C}_5|^2<8.2\times10^{-17}~\rm{GeV}^{-2}$ at the 90% confidence level, playing a unique role in the dark sector search with the charm sector., Comment: 9 pages, 4 figures

Published
2024

39. Study of $D^{+} \to K_{S}^{0}K^{*}(892)^{+}$ in $D^{+} \to K_{S}^{0} K_{S}^{0} \pi^{+}$

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., An, Q., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chang, J. F., Che, G. R., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Chen, Z. Y., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, L., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, X. T., Huang, Y. P., Huang, Y. S., Hussain, T., Hölzken, F., Hüsken, N., der Wiesche, N. in, Jackson, J., Janchiv, S., Jeong, J. H., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., Kühn, W., Lane, J. J., Lavezzi, L., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, K., Li, L. J., Li, L. K., Li, Lei, Li, M. H., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, S. X., Li, T., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Y., Li, X. Z., Li, Y. G., Li, Z. J., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, Y. P., Libby, J., Limphirat, A., Lin, C. C., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F., Liu, F. H., Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. H., Liu, H. M., Liu, Huihui, Liu, J. B., Liu, J. Y., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, X. L., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, J. R., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, L. R., Ma, M. M., Ma, Q. M., Ma, R. Q., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y., Ma, Y. M., Maas, F. E., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pathak, A., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H., Qi, H. R., Qi, M., Qi, T. Y., Qian, S., Qian, W. B., Qiao, C. F., Qiao, X. K., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. P., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J., Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, H. C., Shi, J. L., Shi, J. Y., Shi, Q. Q., Shi, S. Y., Shi, X., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, W. Y., Sun, Y., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tao, Q. T., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, B. L., Wang, Bo, Wang, D. Y., Wang, F., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, M., Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wang, Ziyi, Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, X., Wu, X. H., Wu, Y., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, S. Y., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, H. Y., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W., Xu, W. L., Xu, X. P., Xu, Y. C., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, T., Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, J. H., Yin, Junhao, You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, T., Yu, X. D., Yu, Y. C., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Z. Y., Yue, C. X., Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q. Y., Zhang, R. Y., Zhang, S. H., Zhang, Shulei, Zhang, X. D., Zhang, X. M., Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. Y., Zhang, Z. Z., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, L., Zhao, Lei, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, H., Zhou, J. Y., Zhou, L. P., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhu, A. N., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, T. J., Zhu, W. D., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment
Abstract

Using a data sample of $e^+e^-$ collisions corresponding to an integrated luminosity of 7.93 $\rm fb^{-1}$ collected with the BESIII detector at the center-of-mass energy 3.773~GeV, we perform the first amplitude analysis of the decay $D^{+} \to K_{S}^{0} K_{S}^{0} \pi^{+}$. The absolute branching fraction of $D^{+} \to K_{S}^{0}K_{S}^{0} \pi^{+}$ is measured to be $(2.97 \pm 0.09_{\rm stat.} \pm 0.05_{\rm syst.})\times10^{-3}$. The dominant intermediate process is $D^{+} \to K_{S}^{0}K^{*}(892)^{+}$, whose branching fraction is determined to be $(8.72 \pm 0.28_{\rm stat.} \pm 0.15_{\rm syst.}) \times 10^{-3}$, including all the $K^*(892)^+$ decays.

Published
2024

40. Measurement of Born cross sections of $e^+e^-\to\Xi^0\bar{\Xi}^0$ and search for charmonium(-like) states at $\sqrt{s}$ = 3.51-4.95 GeV

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chai, X. Y., Chang, J. F., Che, G. R., Che, Y. Z., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Chen, Z. Y., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, L., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, Q. P., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, X. T., Huang, Y. P., Huang, Y. S., Hussain, T., Hölzken, F., Hüsken, N., der Wiesche, N. in, Jackson, J., Janchiv, S., Jeong, J. H., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., Kühn, W., Lavezzi, L., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, K., Li, K. L., Li, L. J., Li, L. K., Li, Lei, Li, M. H., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, S. X., Li, T., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Y., Li, X. Z., Li, Y. G., Li, Z. J., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, Y. P., Libby, J., Limphirat, A., Lin, C. C., Lin, C. X., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F., Liu, F. H., Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. H., Liu, H. M., Liu, Huihui, Liu, J. B., Liu, J. Y., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, Liang, Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, X. L., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, J. R., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, L. R., Ma, M. M., Ma, Q. M., Ma, R. Q., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y. M., Maas, F. E., MacKay, I., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pathak, A., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H., Qi, H. R., Qi, M., Qi, T. Y., Qian, S., Qian, W. B., Qiao, C. F., Qiao, X. K., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. P., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, M. Q., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J., Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, J. L., Shi, J. Y., Shi, Q. Q., Shi, S. Y., Shi, X., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, S. S, Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, W. Y., Sun, Y., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tao, Q. T., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, B. L., Wang, Bo, Wang, D. Y., Wang, F., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, M., Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. H., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wang, Ziyi, Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, X., Wu, X. H., Wu, Y., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, S. Y., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, H. Y., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W., Xu, W. L., Xu, X. P., Xu, Y., Xu, Y. C., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, J. H., Yang, T., Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, J. H., Yin, Junhao, You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, M. C., Yu, T., Yu, X. D., Yu, Y. C., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Z. Y., Yue, C. X., Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q. Y., Zhang, R. Y., Zhang, S. H., Zhang, Shulei, Zhang, X. M., Zhang, X. Y, Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. Y., Zhang, Z. Z., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, L., Zhao, Lei, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, H., Zhou, J. Y., Zhou, L. P., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhou, Z. C., Zhu, A. N., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, T. J., Zhu, W. D., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment
Abstract

Using $e^+e^-$ collision data collected by the BESIII detector at BEPCII corresponding to an integrated luminosity of 30 $\rm fb^{-1}$, we measure Born cross sections and effective form factors for the process $e^+e^-\to\Xi^0\bar{\Xi}^0$ at forty-five center-of-mass energies between 3.51 and 4.95 GeV. The dressed cross section is fitted, assuming a power-law function plus a charmonium(-like) state, i.e., $\psi(3770)$, $\psi(4040)$, $\psi(4160)$, $\psi(4230)$, $\psi(4360)$, $\psi(4415)$ or $\psi(4660)$. No significant charmonium(-like) state decaying into $\Xi^0\bar\Xi^0$ is observed. Upper limits at the 90% confidence level on the product of the branching fraction and the electronic partial width are provided for each decay. In addition, ratios of the Born cross sections and the effective form factors for $e^+e^-\to\Xi^0\bar{\Xi}^0$ and $e^+e^-\to\Xi^-\bar{\Xi}^+$ are also presented to test isospin symmetry and the vector meson dominance model., Comment: 22 pages, 2 tables, 4 figures

Published
2024

41. Search for $h_c \to \pi^+\pi^-J/\psi$ via $\psi(3686)\to \pi^0h_c$

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chai, X. Y., Chang, J. F., Che, G. R., Che, Y. Z., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, J. J., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, Q. P., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, P., Huang, X. T., Huang, Y. P., Huang, Y. S., Hussain, T., Hölzken, F., Hüsken, N., der Wiesche, N. in, Jackson, J., Janchiv, S., Jeong, J. H., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., Kühn, W., Lan, W. N., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, K., Li, K. L., Li, L. J., Li, L. K., Li, Lei, Li, M. H., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, T., Li, T. Y., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Y., Li, X. Z., Li, Y., Li, Y. G., Li, Z. J., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, Y. P., Libby, J., Limphirat, A., Lin, C. C., Lin, C. X., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F., Liu, F. H., Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. H., Liu, H. M., Liu, Huihui, Liu, J. B., Liu, J. Y., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, J. R., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, L. R., Ma, M. M., Ma, Q. M., Ma, R. Q., Ma, R. Y., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y. M., Maas, F. E., MacKay, I., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Y. H., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pathak, A., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H., Qi, H. R., Qi, M., Qian, S., Qian, W. B., Qiao, C. F., Qiao, J. H., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. P., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, M. Q., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J., Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, J. L., Shi, J. Y., Shi, S. Y., Shi, X., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, S. S, Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, Y., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tao, Q. T., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, Bo, Wang, C., Wang, D. Y., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, M., Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. H., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, Lianjie, Wu, X., Wu, X. H., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, H., Xiao, S. Y., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W., Xu, W. L., Xu, X. P., Xu, Y., Xu, Y. C., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, W. P., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, J. H., Yang, R. J., Yang, T., Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Y. Z., Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, J. H., Yin, Junhao, You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, M. C., Yu, T., Yu, X. D., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Z. Y., Yue, C. X., Yue, Ying, Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q., Zhang, Q. Y., Zhang, R. Y., Zhang, S. H., Zhang, Shulei, Zhang, X. M., Zhang, X. Y, Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. X., Zhang, Z. Y., Zhang, Z. Z., Zhang, Zh. Zh., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, L., Zhao, Lei, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, X. R., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, H., Zhou, J. Y., Zhou, L. P., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhou, Z. C., Zhu, A. N., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, T. J., Zhu, W. D., Zhu, W. Z., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment
Abstract

Using $(2712.4 \pm 14.3) \times 10^6~\psi$(3686) events collected with the BESIII detector operating at the BEPCII collider, we search for the hadronic transition $h_c \to \pi^+\pi^-J/\psi$ via $\psi(3686)\to \pi^0 h_c$. No significant signal is observed. We set the most stringent upper limits to date on the branching fractions $\mathcal{B}(\psi(3686)\to \pi^0 h_c)\times\mathcal{B}(h_c\to\pi^+\pi^-J/\psi)$ and $\mathcal{B}(h_c \to \pi^+\pi^-J/\psi)$ at the 90$\%$ confidence level, which are determined to be $6.7\times 10^{-7}$ and $9.4 \times10^{-4}$, respectively.

Published
2024

42. Measurement of the Decay $\Xi^{0}\to\Lambda\gamma$ with Entangled $\Xi^{0}\bar{\Xi}^{0}$ Pairs

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., An, Q., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chang, J. F., Che, G. R., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Chen, Z. Y., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, L., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, X. T., Huang, Y. P., Huang, Y. S., Hussain, T., Hölzken, F., Hüsken, N., der Wiesche, N. in, Jackson, J., Janchiv, S., Jeong, J. H., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., Kühn, W., Lane, J. J., Lavezzi, L., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, K., Li, L. J., Li, L. K., Li, Lei, Li, M. H., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, S. X., Li, T., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Y., Li, X. Z., Li, Y. G., Li, Z. J., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, Y. P., Libby, J., Limphirat, A., Lin, C. C., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F., Liu, F. H., Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. H., Liu, H. M., Liu, Huihui, Liu, J. B., Liu, J. Y., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, X. L., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, J. R., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, L. R., Ma, M. M., Ma, Q. M., Ma, R. Q., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y., Ma, Y. M., Maas, F. E., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pathak, A., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H., Qi, H. R., Qi, M., Qi, T. Y., Qian, S., Qian, W. B., Qiao, C. F., Qiao, X. K., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. P., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J., Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, H. C., Shi, J. L., Shi, J. Y., Shi, Q. Q., Shi, S. Y., Shi, X., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, W. Y., Sun, Y., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tao, Q. T., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, B. L., Wang, Bo, Wang, D. Y., Wang, F., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, M., Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wang, Ziyi, Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, X., Wu, X. H., Wu, Y., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, S. Y., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, H. Y., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W., Xu, W. L., Xu, X. P., Xu, Y. C., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, T., Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, J. H., Yin, Junhao, You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, T., Yu, X. D., Yu, Y. C., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Z. Y., Yue, C. X., Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q. Y., Zhang, R. Y., Zhang, S. H., Zhang, Shulei, Zhang, X. D., Zhang, X. M., Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. Y., Zhang, Z. Z., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, L., Zhao, Lei, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, H., Zhou, J. Y., Zhou, L. P., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhu, A. N., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, T. J., Zhu, W. D., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment
Abstract

In this Letter, a systematic study of the weak radiative hyperon decay $\Xi^{0}\to\Lambda\gamma$ at an electron-positron collider using entangled $\Xi^{0}\bar{\Xi}^{0}$ pair events is presented. The absolute branching fraction for this decay has been measured for the first time, and is $\left(1.347 \pm 0.066_{\mathrm stat.}\pm0.054_{\mathrm syst.}\right)\times 10^{-3}$. The decay asymmetry parameter, which characterizes the effect of parity violation in the decay, is determined to be $-0.741 \pm 0.062_{\mathrm stat.}\pm 0.019_{\mathrm syst.}$. The obtained results are consistent with the world average values within the uncertainties, offering valuable insights into the underlying mechanism governing the weak radiative hyperon decays. The charge conjugation parity ($CP$) symmetries of branching fraction and decay asymmetry parameter in the decay are also studied. No statistically significant violation of charge conjugation parity symmetry is observed., Comment: 10 pages, 3 figures

Published
2024

43. Model-independent determination of the strong-phase difference between $D^0$ and $\bar{D}^0 \to \pi^+\pi^-\pi^+\pi^-$ decays

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., An, Q., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chai, X. Y., Chang, J. F., Che, G. R., Che, Y. Z., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Chen, Z. Y., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, L., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, X. T., Huang, Y. P., Huang, Y. S., Hussain, T., Hölzken, F., Hüsken, N., der Wiesche, N. in, Jackson, J., Janchiv, S., Jeong, J. H., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., Kühn, W., Lavezzi, L., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, K., Li, K. L., Li, L. J., Li, L. K., Li, Lei, Li, M. H., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, S. X., Li, T., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Y., Li, X. Z., Li, Y. G., Li, Z. J., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, Y. P., Libby, J., Limphirat, A., Lin, C. C., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F., Liu, F. H., Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. H., Liu, H. M., Liu, Huihui, Liu, J. B., Liu, J. Y., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, X. L., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, J. R., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, L. R., Ma, M. M., Ma, Q. M., Ma, R. Q., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y. M., Maas, F. E., MacKay, I., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pathak, A., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H., Qi, H. R., Qi, M., Qi, T. Y., Qian, S., Qian, W. B., Qiao, C. F., Qiao, X. K., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. P., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, M. Q., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J., Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, H. C., Shi, J. L., Shi, J. Y., Shi, Q. Q., Shi, S. Y., Shi, X., Shi, X. D., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, S. S, Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, W. Y., Sun, Y., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tao, Q. T., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, B. L., Wang, Bo, Wang, D. Y., Wang, F., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, M., Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wang, Ziyi, Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, X., Wu, X. H., Wu, Y., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, S. Y., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, H. Y., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W., Xu, W. L., Xu, X. P., Xu, Y., Xu, Y. C., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, J. H., Yang, T., Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, J. H., Yin, Junhao, You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, M. C., Yu, T., Yu, X. D., Yu, Y. C., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Z. Y., Yue, C. X., Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q. Y., Zhang, R. Y., Zhang, S. H., Zhang, Shulei, Zhang, X. M., Zhang, X. Y, Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. Y., Zhang, Z. Z., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, L., Zhao, Lei, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, H., Zhou, J. Y., Zhou, L. P., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhou, Z. C., Zhu, A. N., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, T. J., Zhu, W. D., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment
Abstract

Measurements of the strong-phase difference between $D^0$ and $\bar{D}^0\to\pi^+\pi^-\pi^+\pi^-$ are performed in bins of phase space. The study exploits a sample of quantum-correlated $D\bar{D}$ mesons collected by the BESIII experiment in $e^+e^-$ collisions at a center-of-mass energy of 3.773~GeV, corresponding to an integrated luminosity of 2.93~fb$^{-1}$. Here, $D$ denotes a neutral charm meson in a superposition of flavor eigenstates. The reported results are valuable for measurements of the $C\!P$-violating phase $\gamma$ (also denoted $\phi_3$) in $B^\pm \to DK^\pm$, $D \to \pi^+\pi^-\pi^+\pi^-$ decays, and the binning schemes are designed to provide good statistical sensitivity to this parameter. The expected uncertainty on $\gamma$ arising from the precision of the strong-phase measurements, when applied to very large samples of $B$-meson decays, is around $1.5^\circ$ or $2^\circ$, depending on the binning scheme. The binned strong-phase parameters are combined to give a value of $F_+^{4\pi} = 0.746 \pm 0.010 \pm 0.004$ for the $C\!P$-even fraction of $D^0 \to \pi^+\pi^-\pi^+\pi^-$ decays, which is around 30\% more precise than the previous best measurement of this quantity.

Published
2024

44. Search for the rare decay $J/\psi \to \gamma D^0+c.c.$ at BESIII

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., An, Q., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chai, X. Y., Chang, J. F., Che, G. R., Che, Y. Z., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, G. F., Fan, J. J., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, Q. P., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, P., Huang, X. T., Huang, Y. P., Huang, Y. S., Hussain, T., Hölzken, F., Hüsken, N., der Wiesche, N. in, Jackson, J., Janchiv, S., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., Kühn, W., Lan, W. N., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, K., Li, K. L., Li, L. J., Li, Lei, Li, M. H., Li, P. L., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, T., Li, T. Y., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Y., Li, X. Z., Li, Y., Li, Y. G., Li, Z. J., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, Y. P., Libby, J., Limphirat, A., Lin, C. C., Lin, C. X., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F., Liu, F. H., Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. H., Liu, H. M., Liu, Huihui, Liu, J. B., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, J. R., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, L. R., Ma, Q. M., Ma, R. Q., Ma, R. Y., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y. M., Maas, F. E., MacKay, I., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Y. H., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pathak, A., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H. R., Qi, M., Qian, S., Qian, W. B., Qiao, C. F., Qiao, J. H., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. P., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, M. Q., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J., Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, J. L., Shi, J. Y., Shi, S. Y., Shi, X., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, S. S, Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, Bo, Wang, C., Wang, D. Y., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, L. W., Wang, M., Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. H., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, Lianjie, Wu, X., Wu, X. H., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, H., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W. L., Xu, X. P., Xu, Y., Xu, Y. C., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, W. P., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, J. H., Yang, R. J., Yang, T., Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Y. Z., Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, Junhao, You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, M. C., Yu, T., Yu, X. D., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Z. Y., Yue, C. X., Yue, Ying, Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q., Zhang, Q. Y., Zhang, R. Y., Zhang, S. H., Zhang, Shulei, Zhang, X. M., Zhang, X. Y, Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. X., Zhang, Z. Y., Zhang, Z. Z., Zhang, Zh. Zh., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, L., Zhao, Lei, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, X. R., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, H., Zhou, J. Y., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhou, Z. C., Zhu, A. N., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, T. J., Zhu, W. D., Zhu, W. J., Zhu, W. Z., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment
Abstract

Using $(10087\pm44)\times10^6J/\psi$ events collected with the BESIII detector, we search for the rare decay $J/\psi \to \gamma D^0+c.c.$ for the first time. No obvious signal is observed and the upper limit on the branching fraction is determined to be ${\cal B}(J/\psi \to \gamma D^{0}+c.c.)< 9.1 \times 10^{-8}$ at 90\% confidence level.

Published
2024

45. Search for $\eta_c(2S)\to\omega\omega$ and $\omega\phi$ decays and measurements of $\chi_{cJ}\to\omega\omega$ and $\omega\phi$ in $\psi(2S)$ radiative processes

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., An, Q., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chang, J. F., Che, G. R., Che, Y. Z., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Chen, Z. Y., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, L., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, X. T., Huang, Y. P., Huang, Y. S., Hussain, T., Hölzken, F., Hüsken, N., der Wiesche, N. in, Jackson, J., Janchiv, S., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., Kühn, W., Lane, J. J., Lavania, A., Lavezzi, L., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, K., Li, K. L., Li, L. J., Li, L. K., Li, Lei, Li, M. H., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, S. X., Li, T., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Y., Li, X. Z., Li, Y. G., Li, Z. J., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, Y. P., Libby, J., Limphirat, A., Lin, C. C., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F., Liu, F. H., Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. H., Liu, H. M., Liu, Huihui, Liu, J. B., Liu, J. Y., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, X. L., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, J. R., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, L. R., Ma, M. M., Ma, Q. M., Ma, R. Q., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y. M., Maas, F. E., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H., Qi, H. R., Qi, M., Qi, T. Y., Qian, S., Qian, W. B., Qiao, C. F., Qiao, X. K., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. P., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, M. Q., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J., Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, J. L., Shi, J. Y., Shi, Q. Q., Shi, S. Y., Shi, X., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, S. S, Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, W. Y., Sun, Y., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tao, Q. T., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, B. L., Wang, Bo, Wang, D. Y., Wang, F., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, L. W., Wang, M., Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. H., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wang, Ziyi, Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, X., Wu, X. H., Wu, Y., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, S. Y., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, H. Y., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W., Xu, W. L., Xu, X. P., Xu, Y., Xu, Y. C., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, J. H., Yang, T., Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, J. H., Yin, Junhao, You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, M. C., Yu, T., Yu, X. D., Yu, Y. C., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Z. Y., Yue, C. X., Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q. Y., Zhang, R. Y., Zhang, S. H., Zhang, Shulei, Zhang, X. D., Zhang, X. M., Zhang, X. Y, Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. Y., Zhang, Z. Z., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, L., Zhao, Lei, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, J. Y., Zhou, L. P., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhu, A. N., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, T. J., Zhu, W. D., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment, High Energy Physics - Phenomenology
Abstract

Using $(2712\pm 14)$ $\times$ 10$^{6}$ $\psi(2S)$ events collected with the BESIII detector at the BEPCII collider, we search for the decays $\eta_{c}(2S)\to\omega\omega$ and $\eta_{c}(2S)\to\omega\phi$ via the process $\psi(2S)\to\gamma\eta_{c}(2S)$. Evidence of $\eta_{c}(2S)\to\omega\omega$ is found with a statistical significance of $3.2\sigma$. The branching fraction is measured to be $\mathcal{B}(\eta_{c}(2S)\to\omega\omega)=(5.65\pm3.77(\rm stat.)\pm5.32(\rm syst.))\times10^{-4}$. No statistically significant signal is observed for the decay $\eta_{c}(2S)\to\omega\phi$. The upper limit of the branching fraction at the 90\% confidence level is determined to be $\mathcal{B}(\psi(2S)\to\gamma\eta_{c}(2S),\eta_{c}(2S)\to\omega\phi)<2.24\times 10^{-7}$. We also update the branching fractions of $\chi_{cJ}\to \omega\omega$ and $\chi_{cJ}\to\omega\phi$ decays via the $\psi(2S)\to\gamma\chi_{cJ}$ transition. The branching fractions are determined to be $\mathcal{B}(\chi_{c0}\to\omega\omega)=(10.63\pm0.11\pm0.46)\times 10^{-4}$, $\mathcal{B}(\chi_{c1}\to\omega\omega)=(6.39\pm0.07\pm0.29)\times 10^{-4}$, $\mathcal{B}(\chi_{c2}\to\omega\omega)=(8.50\pm0.08\pm0.38)\times 10^{-4}$, $\mathcal{B}(\chi_{c0}\to\omega\phi)=(1.18\pm0.03\pm0.05)\times 10^{-4}$, $\mathcal{B}(\chi_{c1}\to\omega\phi)=(2.03\pm0.15\pm0.12)\times 10^{-5}$, and $\mathcal{B}(\chi_{c2}\to\omega\phi)=(9.37\pm1.07\pm0.59)\times 10^{-6}$, where the first uncertainties are statistical and the second are systematic.

Published
2024

46. Analysis of the dynamics of the decay $D^{+}\to K_{S}^{0} \pi^{0} e^{+}\nu_{e}$

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., An, Q., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chai, X. Y., Chang, J. F., Che, G. R., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Chen, Z. Y., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, L., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, X. T., Huang, Y. P., Huang, Y. S., Hussain, T., Hölzken, F., Hüsken, N., der Wiesche, N. in, Jackson, J., Janchiv, S., Jeong, J. H., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., Kühn, W., Lane, J. J., Lavezzi, L., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, K., Li, K. L., Li, L. J., Li, L. K., Li, Lei, Li, M. H., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, S. X., Li, T., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Y., Li, X. Z., Li, Y. G., Li, Z. J., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, Y. P., Libby, J., Limphirat, A., Lin, C. C., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F., Liu, F. H., Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. H., Liu, H. M., Liu, Huihui, Liu, J. B., Liu, J. Y., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, X. L., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, J. R., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, L. R., Ma, M. M., Ma, Q. M., Ma, R. Q., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y. M., Maas, F. E., MacKay, I., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pathak, A., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H., Qi, H. R., Qi, M., Qi, T. Y., Qian, S., Qian, W. B., Qiao, C. F., Qiao, X. K., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. P., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J., Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, H. C., Shi, J. L., Shi, J. Y., Shi, Q. Q., Shi, S. Y., Shi, X., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, S. S, Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, W. Y., Sun, Y., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tao, Q. T., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, B. L., Wang, Bo, Wang, D. Y., Wang, F., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, M., Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wang, Ziyi, Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, X., Wu, X. H., Wu, Y., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, S. Y., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, H. Y., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W., Xu, W. L., Xu, X. P., Xu, Y., Xu, Y. C., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, T., Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, J. H., Yin, Junhao, You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, M. C., Yu, T., Yu, X. D., Yu, Y. C., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Z. Y., Yue, C. X., Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q. Y., Zhang, R. Y., Zhang, S. H., Zhang, Shulei, Zhang, X. M., Zhang, X. Y, Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. Y., Zhang, Z. Z., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, L., Zhao, Lei, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, H., Zhou, J. Y., Zhou, L. P., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhou, Z. C., Zhu, A. N., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, T. J., Zhu, W. D., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment
Abstract

The branching fraction of $D^+\to K_{S}^{0} \pi^{0}e^+\nu_e$ is measured for the first time using $7.93~\mathrm{fb}^{-1}$ of $e^+e^-$ annihilation data collected at the center-of-mass energy $\sqrt{s}=3.773$~GeV with the BESIII detector operating at the BEPCII collider, and is determined to be ${\mathcal B}$($D^+\to K_S^0\pi^0e^+\nu_e$) = $(0.881~\pm~0.017_{\rm stat.}~\pm~0.016_{\rm syst.})$\%. Based on an analysis of the $D^+\to K_S^0\pi^0e^+\nu_e$ decay dynamics, we observe the $S\text{-}{\rm wave}$ and $P$-wave components with fractions of $f_{S\text{-}{\rm wave}}$ = $(6.13~\pm~0.27_{\rm stat.}~\pm ~0.30_{\rm syst.})\%$ and $f_{\bar K^{*}(892)^0}$ = $(93.88~\pm~0.27_{\rm stat.}~\pm~0.29_{\rm syst.})$\%, respectively. From these results, we obtain the branching fractions ${\mathcal B}$($D^+\to (K_S^0\pi^0)_{S\text{-}{\rm wave}}~e^+\nu_e$) = $(5.41~\pm~0.35_{\rm stat.}~\pm~0.37_{\rm syst.})\times10^{-4}$ and ${\mathcal B}$($D^+\to \bar K^{*}(892)^0e^+\nu_e$) = $(4.97~\pm~0.11_{\rm stat.}~\pm~0.12_{\rm syst.})$\%. In addition, the hadronic form-factor ratios of $D^{+} \to \bar {K}^{*}(892)^0e^+\nu_e$ at $q^2=0$, assuming a single-pole dominance parameterization, are determined to be $r_V=\frac{V(0)}{A_1(0)}= 1.43~\pm~0.07_{\rm stat.}~\pm~0.03_{\rm syst.}$ and $r_2=\frac{A_2(0)}{A_1(0)}=0.72~\pm~0.06_{\rm stat.}~\pm~0.02_{\rm syst.}$.

Published
2024

47. Measurement of the Branching Fraction of \boldmath{$\psi(2S) \to \gamma \pi^0$}

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., An, Q., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chai, X. Y., Chang, J. F., Che, G. R., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Chen, Z. Y., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, L., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, X. T., Huang, Y. P., Huang, Y. S., Hussain, T., Hölzken, F., Hüsken, N., der Wiesche, N. in, Jackson, J., Janchiv, S., Jeong, J. H., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., Kühn, W., Lane, J. J., Lavezzi, L., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, K., Li, K. L., Li, L. J., Li, L. K., Li, Lei, Li, M. H., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, S. X., Li, T., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Y., Li, X. Z., Li, Y. G., Li, Z. J., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, Y. P., Libby, J., Limphirat, A., Lin, C. C., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F., Liu, F. H., Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. H., Liu, H. M., Liu, Huihui, Liu, J. B., Liu, J. Y., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, X. L., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, J. R., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, L. R., Ma, M. M., Ma, Q. M., Ma, R. Q., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y. M., Maas, F. E., MacKay, I., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pathak, A., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H., Qi, H. R., Qi, M., Qi, T. Y., Qian, S., Qian, W. B., Qiao, C. F., Qiao, X. K., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. P., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J., Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, H. C., Shi, J. L., Shi, J. Y., Shi, Q. Q., Shi, S. Y., Shi, X., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, S. S, Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, W. Y., Sun, Y., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tao, Q. T., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, B. L., Wang, Bo, Wang, D. Y., Wang, F., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, M., Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wang, Ziyi, Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, X., Wu, X. H., Wu, Y., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, S. Y., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, H. Y., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W., Xu, W. L., Xu, X. P., Xu, Y., Xu, Y. C., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, T., Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, J. H., Yin, Junhao, You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, M. C., Yu, T., Yu, X. D., Yu, Y. C., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Z. Y., Yue, C. X., Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q. Y., Zhang, R. Y., Zhang, S. H., Zhang, Shulei, Zhang, X. D., Zhang, X. M., Zhang, X. Y, Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. Y., Zhang, Z. Z., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, L., Zhao, Lei, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, H., Zhou, J. Y., Zhou, L. P., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhou, Z. C., Zhu, A. N., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, T. J., Zhu, W. D., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment
Abstract

Based on $(2712.4\pm14.1)\times10^{6}~\psi(2S)$ events, 7.9 fb$^{-1}$ $\psi(3773)$ data, and 0.8 fb$^{-1}$ off-resonance data samples collected with the BESIII detector, we measure the branching fraction of $\psi(2S)\rightarrow\gamma\pi^{0}$ and $e^{+}e^{-}\rightarrow\gamma\pi^{0}$ form factor at momentum transfers $Q^{2}\sim13$ GeV$^{2}$. The $e^{+}e^{-}\rightarrow\gamma\pi^{0}$ cross section is fitted with considering the interference between the $\psi(2S)$ and continuum amplitudes and two solutions are found, ${\cal B}=3.74\times10^{-7}$ with $\phi=3.93$ rad and ${\cal B}=7.87\times10^{-7}$ with $\phi=2.08$ rad. Here, ${\cal B}$ is the branching fraction of $\psi(2S)\rightarrow\gamma\pi^{0}$ and $\phi$ is the relative phase angle between the $\psi(2S)$ and continuum amplitudes. Due to insufficient off-resonance data, the branching fraction ${\cal B}(\psi(2S)\rightarrow\gamma\pi^{0})$ is determined to be in the range $[2.7, 9.7]\times10^{-7}$ within one standard deviation of the contour region.

Published
2024

48. Measurement of $\Sigma^+$ transverse polarization in $e^+e^-$ collisions at $\sqrt{s} = 3.68-3.71$ GeV

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., An, Q., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chang, J. F., Che, G. R., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Chen, Z. Y., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, L., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, X. T., Huang, Y. P., Huang, Y. S., Hussain, T., H\ölzken, F., H\üsken, N., der Wiesche, N. in, Jackson, J., Janchiv, S., Jeong, J. H., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., K\ühn, W., Lane, J. J., Larin, P., Lavezzi, L., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, K., Li, L. J., Li, L. K., Li, Lei, Li, M. H., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, S. X., Li, T., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Y., Li, X. Z., Li, Y. G., Li, Z. J., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, L. Z., Liao, Y. P., Libby, J., Limphirat, A., Lin, C. C., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F., Liu, F. H., Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. H., Liu, H. M., Liu, Huihui, Liu, J. B., Liu, J. Y., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, X. L., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, J. R., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, M. M., Ma, Q. M., Ma, R. Q., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y., Ma, Y. M., Maas, F. E., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pathak, A., Patteri, P., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H., Qi, H. R., Qi, M., Qi, T. Y., Qian, S., Qian, W. B., Qiao, C. F., Qiao, X. K., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. P., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J., Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, H. C., Shi, J. L., Shi, J. Y., Shi, Q. Q., Shi, S. Y., Shi, X., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, W. Y., Sun, Y., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tao, Q. T., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, B. L., Wang, Bo, Wang, D. Y., Wang, F., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, M., Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wang, Ziyi, Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, X., Wu, X. H., Wu, Y., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, S. Y., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, H. Y., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W., Xu, W. L., Xu, X. P., Xu, Y. C., Xu, Z. P., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, T., Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, J. H., You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, T., Yu, X. D., Yu, Y. C., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Z. Y., Yue, C. X., Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q. Y., Zhang, R. Y., Zhang, S. H., Zhang, Shulei, Zhang, X. D., Zhang, X. M., Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. Y., Zhang, Z. Z., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, L., Zhao, Lei, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, H., Zhou, J. Y., Zhou, L. P., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, S. Q., Zhu, T. J., Zhu, W. D., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment
Abstract

Using $e^+e^-$ collision data collected with the BESIII detector at seven energy points ranging from 3.68 to 3.71 GeV and corresponding to an integrated luminosity of $652.1~{\rm pb^{-1}}$, we present an energy-dependent measurement of the transverse polarization, relative phase and modulus ratio of the electromagnetic form factors of the $\Sigma^+$ hyperon in the $e^+e^- \to \Sigma^+ \bar{\Sigma}^-$ reaction. These results are helpful to understand the production mechanism of the $\Sigma^+$-$\bar\Sigma^-$ pairs., Comment: 21 pages, 2 tables, 5 figures

Published
2024

49. Observation of $\eta_{c}(2S) \to K^{+}K^{-}\eta$

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., An, Q., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chang, J. F., Che, G. R., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Chen, Z. Y., Cheng, L. N., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, L., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, X. T., Huang, Y. P., Huang, Y. S., Hussain, T., Hölzken, F., Hüsken, N., der Wiesche, N. in, Jackson, J., Janchiv, S., Jeong, J. H., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., Kühn, W., Lane, J. J., Larin, P., Lavezzi, L., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, K., Li, L. J., Li, L. K., Li, Lei, Li, M. H., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, S. X., Li, T., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Y., Li, X. Z., Li, Y. G., Li, Z. J., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, L. Z., Liao, Y. P., Libby, J., Limphirat, A., Lin, C. C., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F., Liu, F. H., Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. H., Liu, H. M., Liu, Huihui, Liu, J. B., Liu, J. Y., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, X. L., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, J. R., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, M. M., Ma, Q. M., Ma, R. Q., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y., Ma, Y. M., Maas, F. E., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pathak, A., Patteri, P., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H., Qi, H. R., Qi, M., Qi, T. Y., Qian, S., Qian, W. B., Qiao, C. F., Qiao, X. K., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J., Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, H. C., Shi, J. L., Shi, J. Y., Shi, Q. Q., Shi, S. Y., Shi, X., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, W. Y., Sun, Y., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tao, Q. T., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, B. L., Wang, Bo, Wang, D. Y., Wang, F., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, M., Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wang, Ziyi, Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, X., Wu, X. H., Wu, Y., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, S. Y., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, H. Y., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W., Xu, W. L., Xu, X. P., Xu, Y. C., Xu, Z. P., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, T., Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, J. H., You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, T., Yu, X. D., Yu, Y. C., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Z. Y., Yue, C. X., Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q. Y., Zhang, R. Y., Zhang, S. H., Zhang, Shulei, Zhang, X. D., Zhang, X. M., Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. Y., Zhang, Z. Z., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, L., Zhao, Lei, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, H., Zhou, J. Y., Zhou, L. P., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, S. Q., Zhu, T. J., Zhu, W. D., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment
Abstract

By analyzing $(27.12 \pm 0.14)\times10^{8}$ $\psi(3686)$ events accumulated with the BESIII detector, the decay $\eta_{c}(2S) \to K^{+} K^{-} \eta$ is observed for the first time with a significance of $6.2\sigma$ after considering systematic uncertainties. The product of the branching fractions of $\psi(3686) \to \gamma\eta_{c}(2S)$ and $\eta_{c}(2S) \to K^{+} K^{-} \eta$ is measured to be $\mathcal{B}(\psi(3686) \to\gamma\eta_{c}(2S))\times \mathcal{B}(\eta_{c}(2S)\to K^{+} K^{-}\eta)=(2.39 \pm 0.32 \pm 0.34) \times 10^{-6}$, where the first uncertainty is statistical, and the second one is systematic. The branching fraction of $\eta_{c}(2S)\to K^{+} K^{-}\eta$ is determined to be $\mathcal{B}(\eta_{c}(2S)\to K^{+} K^{-}\eta) = (3.42 \pm 0.46 \pm 0.48 \pm 2.44) \times 10^{-3}$, where the third uncertainty is due to the branching fraction of $\psi(3686) \to \gamma\eta_{c}(2S)$. Using a recent BESIII measurement of $\mathcal{B} (\eta_{c}(2S) \to K^{+} K^{-}\pi^{0})$, we also determine the ratio between the branching fractions of $\eta_{c}(2S) \to K^{+} K^{-}\eta$ and $\eta_{c}(2S) \to K^{+} K^{-}\pi^{0}$ to be $1.49 \pm 0.22 \pm 0.25$, which is consistent with the previous result of BaBar at a comparable precision level.

Published
2024

50. Search for $X(3872)\to\pi^0\pi^0\chi_{c1,2}$

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., An, Q., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chang, J. F., Che, G. R., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Chen, Z. Y., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, L., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, X. T., Huang, Y. P., Huang, Y. S., Hussain, T., Hölzken, F., Hüsken, N., der Wiesche, N. in, Jackson, J., Janchiv, S., Jeong, J. H., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., Kühn, W., Lane, J. J., Larin, P., Lavezzi, L., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, K., Li, L. J., Li, L. K., Li, Lei, Li, M. H., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, S. X., Li, T., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Y., Li, X. Z., Li, Y. G., Li, Z. J., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, L. Z., Liao, Y. P., Libby, J., Limphirat, A., Lin, C. C., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F., Liu, F. H., Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. H., Liu, H. M., Liu, Huihui, Liu, J. B., Liu, J. Y., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, X. L., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, J. R., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, M. M., Ma, Q. M., Ma, R. Q., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y., Ma, Y. M., Maas, F. E., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pathak, A., Patteri, P., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H., Qi, H. R., Qi, M., Qi, T. Y., Qian, S., Qian, W. B., Qiao, C. F., Qiao, X. K., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J., Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, H. C., Shi, J. L., Shi, J. Y., Shi, Q. Q., Shi, S. Y., Shi, X., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, W. Y., Sun, Y., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tao, Q. T., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, B. L., Wang, Bo, Wang, D. Y., Wang, F., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, M., Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wang, Ziyi, Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, X., Wu, X. H., Wu, Y., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, S. Y., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, H. Y., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W., Xu, W. L., Xu, X. P., Xu, Y. C., Xu, Z. P., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, T., Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, J. H., You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, T., Yu, X. D., Yu, Y. C., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Z. Y., Yue, C. X., Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q. Y., Zhang, R. Y., Zhang, S. H., Zhang, Shulei, Zhang, X. D., Zhang, X. M., Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. Y., Zhang, Z. Z., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, L., Zhao, Lei, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, H., Zhou, J. Y., Zhou, L. P., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, S. Q., Zhu, T. J., Zhu, W. D., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment
Abstract

Using 10.1 fb$^{-1}$ of $e^+e^-$ collision data collected by the BESIII detector with center-of-mass energies between 4.15 GeV and 4.30 GeV, we search for the decays $X(3872)\to\pi^0\pi^0\chi_{c1,2}$, where the $X(3872)$ is produced in $e^+e^-\to\gamma X(3872)$. No evidence above $3\sigma$ is found for either decay. Upper limits at the $90\%$ C.L. on the branching fractions of $X(3872)\to\pi^0\pi^0\chi_{c1,2}$ normalized to the branching fraction of $X(3872)\to\pi^+\pi^-J/\psi$ are set to be $\mathcal{B}(X(3872)\to\pi^0\pi^0\chi_{c1})/\mathcal{B}(X(3872)\to\pi^+\pi^-J/\psi) < 1.1$ and $\mathcal{B}(X(3872)\to\pi^0\pi^0\chi_{c2})/\mathcal{B}(X(3872)\to\pi^+\pi^-J/\psi) < 0.5$, taking into account both statistical and systematic uncertainties., Comment: 12 pages, 4 figures, 6 tables

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results